Introduction {#s1}
============

Tumors are composed of a heterogeneous mix of cell types, including cancer cells and stromal cells such as fibroblasts, macrophages, and other immune cells. How these different cell types interact to enable tumor growth is poorly understood. Environmental context plays an important role in determining how cancer cells use nutrients to proliferate and survive, and non-cancer cells within a tissue can alter nutrient availability ([@bib52]; [@bib58]; [@bib60]; [@bib67]; [@bib83]). There is evidence that different cell populations within tumors can compete for limiting nutrients ([@bib15]; [@bib38]; [@bib95]), and metabolic cooperation between different cell types can also influence tumor phenotypes ([@bib50]; [@bib80]; [@bib84]; [@bib86]). Nevertheless, technical challenges associated with studying the metabolism of individual cell types within a mixed population have limited a complete understanding of the metabolic interactions between cells in tumors. More broadly, this challenge has been a barrier to study how cells use nutrients differently within tissues to support both normal and disease physiology.

Cancer cell metabolism in culture can differ from the metabolism of tumors in vivo ([@bib8]; [@bib14]; [@bib23]; [@bib57]; [@bib59]; [@bib76]; [@bib85]). This can at least partially be ascribed to changes in cancer cell metabolism that are driven by different nutrients present in the extracellular environment; however, another major difference between cell culture and tumors is the presence of additional cell types within tumors that are absent from most culture systems. The presence of many different cell types complicates the ability to characterize cancer cell metabolism in tumors, particularly in cases where a minority of the tumor is composed of cancer cells. For instance, cancer cells are a minority cell type in pancreatic ductal adenocarcinoma (PDAC) tumors ([@bib28]), and an understanding of cell metabolism in these tumors requires de-convolution of cancer-specific and stroma-specific phenotypes. Furthermore, there is evidence that the metabolism of cancer cells and different stromal cells isolated from these tumors can be different from each other when studied in culture ([@bib29]; [@bib34]; [@bib80]), and it is unknown whether the metabolic programs used by different cell populations in culture are also used within PDAC tumors in vivo where environmental conditions are different.

Studies of bulk tumor metabolism fail to capture information about metabolic heterogeneity with regard to different cell types ([@bib90]), and existing approaches are limited in their ability to study functional metabolic phenotypes in different cell populations in intact tissue. A major limitation arises from the fact that metabolic reactions take place on time scales that are faster than the turnover of many metabolic intermediates, complicating metabolite analysis after tumor digestion and cell sorting ([@bib77]). Furthermore, cell sorting exposes cells to conditions that are different from those experienced by cells in tissues and can change metabolism in many ways. For example, sorting can induce mechanical and oxidative stress and reduce the levels of certain metabolites ([@bib9]; [@bib51]; [@bib69]), and even adding small amounts of bovine serum to the sorting buffer was not sufficient to prevent changes in some metabolite levels during cell sorting ([@bib51]). Indeed, isotopic metabolite labeling patterns can be more robust than metabolite levels when assessing metabolites from flow cytometry sorted cells, although labeling can also be affected by cell sorting ([@bib69]). Nevertheless, interpretation of metabolite labeling patterns is influenced by whether cells are at metabolic steady state ([@bib11]), which when coupled with the rapid timescales of metabolism relative to the time needed to isolate cells suggests that new approaches are needed to better understand metabolism of individual cell types within mixed cell populations such as tumors.

To overcome the challenges associated with studying cell metabolism within intact tumors and organoid co-cultures, we adapted an approach based on end-product biomass labeling ([@bib32]; [@bib40]; [@bib46]; [@bib48]; [@bib56]; [@bib78]). This technique has been applied in studies of microbial metabolism and metabolic engineering to better understand mixed populations of bacteria ([@bib30]; [@bib31]; [@bib71]; [@bib94]). Unlike short-lived metabolic intermediates, turnover of end-product macromolecules such as protein is slow relative to the time period needed to isolate tumor cell populations. By assessing the isotope-labeling pattern of end-product biomass generated when cells are exposed to labeled nutrients in a mixed cell population, metabolic differences in nutrient use by different cells can be inferred. We used this approach to uncover a difference in glucose metabolism between cancer cells and fibroblasts in PDAC. Specifically, we find that, relative to fibroblasts, cancer cells within PDAC tumors have increased use of glucose for tricarboxylic acid (TCA) cycle anaplerosis through increased flux through pyruvate carboxylase (PC). This phenotype is not evident when cancer cells and fibroblasts are studied as separate populations in mono-culture, even though PC is necessary for tumor growth in vivo. Furthermore, deletion of PC was insufficient to account for all pyruvate carboxylation activity within cancer cells in a mixed population, revealing that malic enzyme 1 (ME1) also contributes to pyruvate carboxylation in cancer cells when fibroblasts are present and is required for PDAC tumor growth. These data argue that tracing labeled nutrients into stable biomass can be used to reveal metabolic differences between subpopulations of cells in a mixed cell system and to identify phenotypes that depend on the co-existence of multiple cell types.

Results {#s2}
=======

Glucose metabolism in pancreatic tumors {#s2-1}
---------------------------------------

PDAC involves tumors where cancer cells can be a minority cell population ([@bib28]). To better understand glucose metabolism of PDAC tumor tissue in vivo, we infused U-^13^C-glucose into conscious, unrestrained mice ([@bib23]; [@bib43]; [@bib54]) bearing PDAC tumors from autochthonous models that are driven by activating mutations in *Kras* and disruption of *Trp53* function ([@bib6]; [@bib37]). Similar to what has been observed with other mouse cancer models and in humans ([@bib23]; [@bib26]; [@bib36]; [@bib75]), extensive labeling of multiple metabolic intermediates is observed from U-^13^C-glucose in pancreatic tumors and normal pancreas ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[3](#fig1s3){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}, [Figure 1---figure supplement 1---source data 1](#fig1s1sdata1){ref-type="supplementary-material"}, [Figure 1---figure supplement 2---source data 1](#fig1s2sdata1){ref-type="supplementary-material"}, [Figure 1---figure supplement 3---source data 1](#fig1s3sdata1){ref-type="supplementary-material"}).

![Glucose metabolism in PDAC tumors.\
(**A**) Plasma glucose levels over time in autochthonous *LSL-Kras^G12D/+^; Trp53^fl/fl^; Pdx1-Cre* (KP^-/-^C) or autochthonous *LSL-Kras^G12D/+^; Trp53^R172H/+^; Pdx1-Cre* (KPC) pancreatic tumor-bearing mice infused with U-^13^C-glucose at a rate of 0.4 mg/min. n = 3 for each group. Mean +/- SEM is shown. (**B**) Enrichment of fully labeled glucose (M+6) in plasma from the indicated mice following a 6 hr U-^13^C-glucose infusion at a rate of 0.4 mg/min. Non-tumor bearing C57Bl6/J (WT) mice were used to assess metabolite labeling in normal pancreas. WT, n = 4; KP^-/-^C, n = 3, KPC, n = 3. Differences in plasma glucose enrichment were not significant between WT and KP^-/-^C mice (p=0.8723), WT and KPC mice (p=0.1907), or KP^-/-^C and KPC tumor-bearing mice (p=0.1512) based on unpaired, two-tailed student's t tests. Mean +/- SEM is shown. (**C--F**) The fractional labeling of pyruvate (**C**), lactate (**D**), alanine (**E**), and serine (**F**) in pancreas (black), autochthonous KP^-/-^C pancreatic tumors (dark blue), or autochthonous KPC pancreatic tumors (light blue) following a 6 hr U-^13^C-glucose infusion at a rate of 0.4 mg/min. The M+3 isotopomers are shown for each metabolite: n = 3 for each group. Mean +/- SEM is shown. (**G**) Schematic illustrating how U-^13^C-glucose can label TCA cycle intermediates. An M+2 labeling pattern of TCA cycle intermediates can be derived from flux through pyruvate dehydrogenase (PDH) (left) while an M+3 labeling pattern can reflect flux through pyruvate carboxylase (PC) (right). (**H--O**) The fractional labeling of citrate (M+3; WT vs. KP^-/-^C p=0.0012, KP^-/-^C vs. KPC p=0.0084) (**H**), α-ketoglutarate (αKG) (**I**), succinate (**J**), fumarate (**K**), malate (M+3 KP^-/-^C vs. KPC p=0.0156) (**L**), aspartate (M+3 WT vs. KPC p=0.0194) (**M**), glutamate (M+2 WT vs. KP^-/-^C p=0.0089) (**N**), and proline (**O**) in pancreas (black), autochthonous KP^-/-^C pancreatic tumors (dark blue), or autochthonous KPC pancreatic tumors (light blue) following a 6 hr U-^13^C-glucose infusion at a rate of 0.4 mg/min. Significance based on unpaired, Students t-test. The M+2 and M+3 isotopomers are shown for each metabolite, n = 3 for each group. Mean +/- SEM is shown.\
Figure 1---source data 1.Isotope labeling of tumors in U-^13^C- glucose-infused mice with autochthonous PDAC tumors presented in [Figure 1](#fig1){ref-type="fig"}.](elife-56782-fig1){#fig1}

To assess U-^13^C-glucose labeling of metabolites in autochthonous pancreatic tumors arising in the *LSL-Kras^G12D^; Trp53^fl/fl^; Pdx1-Cre* (KP^-/-^C) ([@bib6]) and the *LSL-Kras^G12D^; Trp53^R172H/+;^ Pdx1-Cre* (KPC) ([@bib37]) mouse models, we first confirmed that plasma glucose levels were not changed over the course of the experiment ([Figure 1A](#fig1){ref-type="fig"}). At this rate of glucose infusion, enrichment of ^13^C-glucose in plasma was around 40% in non-tumor-bearing mice, and in both KP^-/-^C and KPC animals ([Figure 1B](#fig1){ref-type="fig"}). Glucose enrichment was not measured in tumors, as glucose is thought to be rapidly metabolized after entry into cells ([@bib61]; [@bib66]; [@bib92]). Under these conditions, labeling of pyruvate and lactate, as well as the glucose-derived amino acids alanine and serine, from U-^13^C-glucose was observed in normal pancreas tissue and in tumors arising in both models ([Figure 1C--F](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}).

Labeling of TCA cycle metabolites was also observed in normal pancreas tissue and in PDAC tumors from both models ([Figure 1G--L](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Carbon from glucose-derived pyruvate can contribute to the TCA cycle via reactions catalyzed by pyruvate dehydrogenase (PDH) or pyruvate carboxylase (PC), and the relative use of these routes of TCA cycle labeling has been inferred from the labeling pattern of TCA cycle intermediates from ^13^C-labeled glucose ([@bib23]; [@bib26]; [@bib36]; [@bib75]). PDH decarboxylates three-carbon pyruvate to two-carbon acetyl-CoA, and therefore if ^13^C-labeled pyruvate is metabolized via PDH, a two carbon (M+2) labeling pattern is observed in TCA cycle metabolites as well as in the amino acid aspartate ([Figure 1G](#fig1){ref-type="fig"}). In contrast, PC carboxylates three-carbon pyruvate to four-carbon oxaloacetate, and therefore if unlabeled CO~2~ is added to ^13^C-labeled pyruvate via this enzyme, a three carbon (M+3) labeling pattern is observed ([Figure 1G](#fig1){ref-type="fig"}). We observed an increase in both M+2 and M+3 labeling of TCA cycle metabolites and the TCA cycle-derived amino acids aspartate and glutamate in KP^-/-^C tumor tissue compared to normal pancreas ([Figure 1H--N](#fig1){ref-type="fig"}). Importantly, despite some aspartate labeling in the plasma of infused mice ([Figure 1---figure supplement 1J](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 1---source data 1](#fig1s1sdata1){ref-type="supplementary-material"}), prior studies of this model have shown that cancer cells cannot take up extracellular aspartate ([@bib81]), arguing that labeled aspartate in plasma contributes minimally to aspartate labeling in cancer cells in PDAC tumors. Proline was not extensively labeled from glucose in pancreas or PDAC tumor tissue from either model, suggesting that glucose carbon contributes minimally to the synthesis of this amino acid ([Figure 1O](#fig1){ref-type="fig"}, [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Of note, in KPC mouse PDAC tumors, we observed higher M+2 labeling of only some TCA cycle metabolites compared to normal pancreas, and did not observe an increase in M+3 metabolite labeling compared to pancreas ([Figure 1H--O](#fig1){ref-type="fig"}), illustrating that glucose labels metabolites differently in bulk tumors arising in each model. These data suggest that glucose contributes to labeling of TCA cycle carbon via reactions that involve PDH and PC in PDAC tumors, although the extent of labeling depends on the PDAC model used.

To further study glucose metabolism in PDAC tumor tissue, we infused control and tumor-bearing KP^-/-^C mice with U-^13^C-glucose at a higher rate in an attempt to increase plasma enrichment of labeled glucose ([@bib23]; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 1---figure supplement 3A--K](#fig1s3){ref-type="fig"}, [Figure 1---figure supplement 2---source data 1](#fig1s2sdata1){ref-type="supplementary-material"}, [Figure 1---figure supplement 3---source data 1](#fig1s3sdata1){ref-type="supplementary-material"}). Plasma glucose levels were increased as a result of this higher infusion rate ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}), and resulted in extensive labeling of glycolytic metabolites and glucose-derived amino acids ([Figure 1---figure supplement 2C--F](#fig1s2){ref-type="fig"}, [Figure 1---figure supplement 2---source data 1](#fig1s2sdata1){ref-type="supplementary-material"}), as well as an increase in M+2 and M+3 labeling of TCA cycle intermediates and related amino acids in pancreatic tumor tissue relative to normal pancreas ([Figure 1---figure supplement 2G--N](#fig1s2){ref-type="fig"}, [Figure 1---figure supplement 2---source data 1](#fig1s2sdata1){ref-type="supplementary-material"}). These data further support that glucose carbon can contribute label to TCA cycle intermediates via pathways that involve PDH and PC in PDAC tumors, but the relative contribution varies based on plasma glucose levels and the PDAC model examined.

Despite both being driven by mutant *Kras* and loss of normal *Trp53* function, differences in the autochthonous KP^-/-^C and KPC PDAC models are known and have been attributed to differences in tumor latency and p53 status, as well as differences in how stromal cell populations interact with cancer cells to support tumor growth ([@bib70]; [@bib87]). Thus, a difference in relative abundance of cancer and non-cancer cells, or in interactions between non-cancer cells and cancer cells, are possible explanations for why differences in glucose labeling are observed across these models. To explore whether the relative abundance of cancer cells in the tumor might affect labeling, we infused mice with pancreatic tumors derived from orthotopic injection of a syngeneic *Kras^G12D^; Trp53^-/-^* pancreatic cancer cell line derived from tumors arising in the KP^-/-^C model ([@bib21]), since cell line transplantation models are thought to result in tumors with a less dense, desmoplastic stroma compared to autochthonous models ([@bib5]; [@bib65]). When compared to adjacent normal pancreas, we observed an increase in M+2 and M+3 labeling of TCA metabolites and aspartate in this orthotopic tumor model ([Figure 1---figure supplement 3L--O](#fig1s3){ref-type="fig"}, [Figure 1---figure supplement 3---source data 1](#fig1s3sdata1){ref-type="supplementary-material"}). Regardless, tumors arising from orthotopic transplantation of murine PDAC cells still contain stroma ([@bib21]). Thus, tumors in all models considered consist of multiple cell types, and cancer cells are known to be a minority cell population in both autochthonous PDAC tumor models. In all cases, metabolite labeling will reflect a weighted average of labeling in all cell types present in the tissue sample and this heterogeneity in cell types in all tissues is a limitation to the use of labeled nutrient infusions to understand the metabolism of cancer cells, or any individual cell population, in tumors or other tissues.

Assessment of pyruvate carboxylation activity in different PDAC tumor cell populations using existing methods {#s2-2}
-------------------------------------------------------------------------------------------------------------

Dissecting the metabolism of individual cell types within a mixed cell population is a barrier to identifying cancer cell-specific liabilities via functional metabolic measurements in tumors such as PDAC. Therefore, we sought to better understand the contribution of cancer cells to the labeling of TCA cycle intermediates from ^13^C-glucose in PDAC tumors. We focused on M+3 labeling of TCA cycle intermediates from glucose, reflective of pyruvate carboxylation activity, because this is a metabolic phenotype observed in tumors that is less prominent in cancer cells in culture ([@bib23]). One existing approach to determine which cell type within the tumor contributes to this activity is to evaluate expression of an enzyme known to catalyze this reaction. Indeed, immunohistochemistry (IHC) analysis of tumors arising in KP^-/-^C mice revealed higher PC expression in cancer cells ([Figure 2A](#fig2){ref-type="fig"}). Analysis of a human pancreatic tumor tissue by IHC shows that human tumors exhibit a range of PC expression levels ([Figure 2---figure supplement 1A--D](#fig2s1){ref-type="fig"}), although higher PC expression is observed in cancer cells compared to stroma ([Figure 2B](#fig2){ref-type="fig"}), similar to findings in human lung tumors ([@bib75]). However, while IHC can be useful to determine relative expression in tumor sections, it does not prove lack of expression by non-cancer cells. Indeed, qPCR analysis of mRNA isolated from sorted cell populations derived from KP^-/-^C tumors trended toward higher PC expression in cancer cells relative to fibroblasts, although PC mRNA was detected in fibroblasts ([Figure 2C](#fig2){ref-type="fig"}). Furthermore, metabolic fluxes can be more dependent on metabolite concentrations than enzyme expression levels ([@bib33]). Therefore, increased enzyme expression may not reflect increased activity in tissues, and argues that while suggestive, expression analysis is not definitive for identifying which cell population is responsible for M+3 TCA cycle labeling from glucose in pancreatic tumors.

![Assessment of pyruvate carboxylase activity in PDAC cancer cells and fibroblasts.\
(**A**) Sections from tumors arising in *LSL-Kras^G12D/+^; Trp53^fl/fl^; Pdx1-Cre* (KP^-/-^C) mice were stained with an antibody against pyruvate carboxylase. Scale bar represents 100 μm. (**B**) Representative image from a human pancreatic tumor tissue microarray that was stained with an antibody against pyruvate carboxylase. Scale bar represents 100 μm. (**C**) Pyruvate carboxylase expression was assessed by qPCR in whole PDAC tumors and different cell populations in sorted from PDAC tumors arising KP^-/-^C mice. The difference in expression between sorted cancer cells and the whole tumor (p=0.5485) or between sorted cancer cells and fibroblasts from tumors was not significant (p=0.0722) based on unpaired, two-tailed student's t-tests. Mean +/- SEM is shown. 36B4 was used as a housekeeping gene control. (**D--F**) The fractional labeling of aspartate (**D**) or malate (**E**) in cultured murine PDAC cells derived from tumors in KP^-/-^C mice (black) and in cultured isolated pancreatic stellate cells (PSCs) (grey) was measured after exposure to U-^13^C-glucose for 24 hr. The M+2 and M+3 isotopomers are shown for each metabolite. Mean +/- SD is shown. (**F**) Fluorescent images of KP^-/-^C PDAC cancer cell organoids expressing tdTomato cultured in DMEM without pyruvate with 10% dialyzed FBS (top) or in the same media conditions with murine PSCs included in the culture (bottom). (**G**) Quantification of tdTomato fluorescence from images in (**G**). Organoid cultures with PSCs included had significantly higher tdTomato fluorescence than organoids cultured without PSCs (p=0.0014) based on an unpaired, two-tailed student's t-test. Mean +/- SD is shown. (**H**) Expression of pyruvate carboxylase as assessed by qPCR in PDAC cancer cells or PSC cells sorted from organoid co-cultures (3D) or in standard 2D culture as indicated. The difference between cancer cells in 3D compared to PSCs in 3D (p=0.1071) was not significant, but the differences between cancer cells in 3D and cancer cells in 2D (p=0.0140), cancer cells in 3D compared to PSCs in 2D (p=0.0209), PSCs in 3D compared to cancer cells in 2D (p\<0.0001), and PSCs in 3D compared to PSCs in 2D (p=0.0014) were significant based on unpaired, two-tailed student's t-tests. Mean +/- SD is shown. (**I--J**) The fractional labeling of aspartate (**I**) or malate (**J**) in murine PDAC organoid-PSC co-cultures was measured after 24 hr of exposure to U-^13^C-glucose. The M+2 and M+3 isotopomers are shown for each metabolite. Mean +/- SD is shown.\
Figure 2---source data 1.Metabolite isotope labeling by U-^13^C- glucose in unsorted organoid-PSC co-cultures.](elife-56782-fig2){#fig2}

Another approach that has been used to determine which cell type(s) within the tumor contribute to a metabolic activity is isolating distinct cell populations and studying them in culture ([@bib20]; [@bib29]; [@bib50]; [@bib80]; [@bib84]; [@bib91]). Pancreatic stellate cells (PSCs) are a type of resident fibroblast in the pancreas which can become activated during tumorigenesis and impact the tumor microenvironment ([@bib12]; [@bib25]). When PDAC cells or PSCs alone are cultured in the presence of ^13^C-glucose in vitro, PSCs exhibit similar or higher M+3 TCA cycle metabolite labeling than cancer cells ([Figure 2D--E](#fig2){ref-type="fig"}), even though the fibroblast cell population exhibited lower PC expression in tumors ([Figure 2A--B](#fig2){ref-type="fig"}). These data further highlight the challenges associated with ascribing functional metabolic phenotypes using enzyme expression alone. Nevertheless, isolated cell populations in culture also may not retain the same functional metabolic phenotypes found within tumor tissue where many different cells compete for available nutrients.

To develop new approaches to study the phenotype of individual cell types in a mixed cell population, we first sought to generate a more tractable system that only involves interactions between two different cell types. One approach is to use organoid cultures involving PDAC cancer cells and fibroblasts ([@bib64]) where nutrient conditions are modified such that cancer cells rely on the presence of the fibroblasts to proliferate. To do this, we generated pancreatic cancer organoid cultures from KP^-/-^C and KPC tumors ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}; [@bib10]), and found that when exposed to a more minimal medium than is commonly used ([@bib10]), pancreatic cancer organoid growth becomes dependent on including PSCs in the culture system ([Figure 2F--G](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1F--G](#fig2s1){ref-type="fig"}). Relevant to the M+3 labeling of TCA cycle-associated metabolites from glucose observed in pancreatic tumors, when sorted from this co-culture organoid system, both cancer cells and PSCs expressed higher levels of PC mRNA compared to PSCs and pancreatic cancer cells in standard monoculture ([Figure 2H](#fig2){ref-type="fig"}). In addition, when U-^13^C-glucose is provided to whole organoid co-cultures comprised of both cancer cells and PSCs, and TCA cycle intermediate labeling is assessed after rapid quenching and extraction of metabolites, M+3 labeling of aspartate and malate was observed ([Figure 2I--J](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1H--K](#fig2s1){ref-type="fig"}, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). These data argue that this organoid co-culture system may provide a model to explore the relative contribution of each cell population to the pyruvate carboxylation phenotype observed when both cell types are present.

Effect of cell sorting on metabolite levels and metabolite labeling from extracellular nutrients {#s2-3}
------------------------------------------------------------------------------------------------

To dissect PDAC cancer cell versus other cell type contributions to specific metabolic activities, we reasoned it would be necessary to isolate each cell type for analysis after exposure to labeled nutrients. To experimentally evaluate the effect of sorting cells from the organoid co-culture system on metabolite levels and labeling from glucose, we cultured AL1376 murine PDAC cells in U-^13^C-glucose and incubated the cells in buffer on ice for various lengths of time to simulate conditions the cells would experience during separation by flow cytometry (up to 240 min) or other antibody based methods, which require a minimum of 10--12 min ([@bib1]; [@bib16]). Metabolite levels and labeling were then measured over time using mass spectrometry, allowing comparison to that observed when metabolism is rapidly quenched (the zero time point). Consistent with the known rapid turnover of metabolites ([@bib77]), the levels ([Figure 3A--D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A--C](#fig3s1){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}) and/or labeling from U-^13^C-glucose ([Figure 3E--H](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1D--F](#fig3s1){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}), of many metabolites changed over the time required to separate cells using antibodies and/or flow cytometry. These changes indicate that metabolism is not at metabolic steady-state where levels and labeling of metabolites are stable over time and could complicate interpretation of some differential isotope labeling patterns ([@bib11]). In fact, changes in metabolite levels and labeling may be even greater when using flow cytometry to sort cells in practice because temperature as well as factors such as mechanical stress are less easily controlled ([@bib9]). While this does not absolutely preclude an ability to gain information from metabolite measurements in sorted cells, assessment of M+3 labeling of TCA cycle intermediates in sorted cell populations from organoids or tumors may not fully portray the contribution of each cell type to the pyruvate carboxylation phenotype observed when material containing multiple cell types is analyzed.

![Turnover of polar metabolites but not protein is fast relative to the time needed to sort cells.\
(**A--D**) Metabolite levels (total ion counts, TIC) of (**A**) aspartate, (**B**) alanine, (**C**) malate, and (**D**) citrate were measured by GC-MS in AL1376 PDAC cells extracted 0--240 min after incubation in PBS on ice to mimic optimal sorting conditions. Mean +/- SD is shown. (**E--H**) Fractional labeling of (**E**) aspartate, (**F**) alanine, (**G**) malate, and (**H**) citrate were measured by GC-MS from cells extracted 0--240 min after incubation in PBS on ice. The M+3 isotopomer is shown. Mean +/- SD is shown. (**I--J**) Fractional labeling of (**I**) aspartate and (**J**) alanine from protein hydrolysates were measured by GC-MS in cells extracted 0--240 min after incubation in PBS on ice. The M+3 isotopomer is shown. Mean +/- SD is shown. Time points analyzed were 0 min (no PBS incubation), 5 min, 30 min, 120 min, or 240 min of incubation in PBS.\
Figure 3---source data 1.Metabolite abundance, metabolite isotope labeling, and protein hydrolysate isotope labeling by U-^13^C- glucose in AL1376 PDAC cells.](elife-56782-fig3){#fig3}

The turnover of protein and nucleic acid is slow relative to metabolites ([@bib77]), which allows gene expression and proteomic analysis in separated cell types to better reflect the state of cells within a mixed population. Because metabolites contribute to protein, lipid, and nucleic acid biomass, and isotope-labeled nutrients can be traced into this biomass ([@bib30]; [@bib31]; [@bib32]; [@bib40]; [@bib46]; [@bib48]; [@bib56]; [@bib71]; [@bib78]; [@bib94]), we reasoned that ^13^C-labeling patterns in biomass might be used to infer the contribution of glucose to different metabolic pathways within a mixed cell population relevant to pancreatic cancer. We confirmed that glucose labeling of protein was stable over the time period needed to sort cells by flow cytometry ([Figure 3I--J](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). We also confirmed that amino acids from protein hydrolysates were detectable in sorted cells from murine PDAC tumors, and were within the linear range of detection by GC-MS even when low cell numbers of less abundant cell populations were recovered from tumors ([Figure 3---figure supplement 1G--L](#fig3s1){ref-type="fig"}). Therefore, examining ^13^C label in amino acids from hydrolyzed protein may be informative of the labeling of free amino acids in tumor cell subpopulations that existed prior to sorting the cells.

Evidence for higher pyruvate carboxylation activity in cancer cells relative to fibroblasts in PDAC models {#s2-4}
----------------------------------------------------------------------------------------------------------

To facilitate sorting of PSCs and PDAC cancer cells from organoid co-cultures and tumors, a *LSL-tdTomato* reporter allele was bred to the KP^-/-^C and KPC PDAC models as a source of tdTomato^+^ cancer cells for both organoid and tumor models. PSCs were isolated from pancreata from mice bearing a *β-actin-GFP* allele to enable sorting of GFP^+^ PSCs for labeling of the PSC population in the organoid co-culture model ([Figure 4A](#fig4){ref-type="fig"}). To determine the relative contribution of ^13^C-glucose to M+3-labeled aspartate in cancer cells and PSCs in the organoid-fibroblast co-culture model, we exposed organoid co-cultures containing tdTomato^+^ cancer cells and GFP^+^ PSCs to U-^13^C-glucose for 1--4 days prior to sorting cancer cells and PSCs, and then hydrolyzed protein for amino acid analysis from each cell population. Over time, similar M+2 protein aspartate labeling was observed between the two cell types, while higher M+3 aspartate labeling was observed in cancer cells as compared to PSCs, suggesting that while the two cell types have similar labeling via reactions involving PDH, the cancer cells appear to have higher pyruvate carboxylation activity ([Figure 4B--C](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). This higher M+3 level was also reflected in the other TCA cycle-derived amino acids glutamate and proline ([Figure 4D--G](#fig4){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), whereas labeling of the glucose-derived amino acids alanine and serine was not higher in cancer cells ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}, [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). We also exposed organoid co-cultures to U-^13^C-glutamine over 4 days and traced the fate of labeled carbon into protein in each cell population. Of note, we observed slightly higher labeling of aspartate from glutamine in protein in PSCs ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 1---source data 1](#fig4s1sdata1){ref-type="supplementary-material"}), matching the lower fractional labeling we observed from glucose. We did not observe other appreciable differences in fractional labeling of glutamate or proline from glutamine in protein between cancer cells and PSCs ([Figure 4---figure supplement 1D--E](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 1---source data 1](#fig4s1sdata1){ref-type="supplementary-material"}). Taken together, these data suggest a differential fate for glucose in these cell types, with increased M+3 labeling of aspartate from glucose carbon in cancer cells relative to PSCs.

![PDAC cancer cells have higher pyruvate carboxylation activity than fibroblasts in organoid co-cultures.\
(**A**) A representative flow cytometry plot showing GFP and tdTomato expression in PSCs and cancer cells respectively from digested organoid-PSC co-cultures. Cells were gated on the single cell, live population. (**B--G**) Fractional labeling of aspartate (**B--C**), glutamate (**D--E**), and proline (**F--G**) in protein hydrolysates from sorted organoid cancer cells (black) and PSCs (blue) after exposure of organoid co-cultures to U-^13^C-glucose for the indicated time. Cancer cells were derived from *LSL-Kras^G12D/+^; Trp53^fl/fl^; Pdx1-Cre; LSL-tdTomato* (KP^-/-^CT) mice. M+2 and M+3 isotopomers are shown as indicated. Each time point represents pooled organoid co-culture samples from one 24-well plate in a representative experiment. (**H**) BFP fluorescence as measured by flow cytometry of a protein synthesis reporter in the indicated cell type isolated from KP^-/-^CT PDAC organoid-PSC co-cultures over time following TMP administration. BFP fluorescence is shown for cancer cells (black) and PSCs (blue). Mean +/- SD is shown. Data were normalized to no TMP controls. (**I**) Schematic illustrating the ^13^C labeling patterns for 3,4-^13^C-glucose or 1-^13^C-pyruvate tracing. TCA cycle metabolites and aspartate are unlabeled from these tracers if metabolized via PDH (left), but result in one carbon labeling (M+1) if metabolized via PC (right). (**J**) Fractional labeling of aspartate M+1 from protein hydrolysates following three days of KP^-/-^CT organoid-PSC co-culture with 1-^13^C-pyruvate. The difference in aspartate M+1 labeling was significant (p=0.0020) using an unpaired student's t test. Mean +/- SD is shown. (**K**) Fractional labeling of aspartate M+1 from protein hydrolysates following 3 days of KP^-/-^CT organoid-PSC co-culture with 3,4-^13^C-glucose. The difference in aspartate M+1 labeling was significant (p=0.0007) using an unpaired student's t test. Mean +/- SD is shown.\
Figure 4---source data 1.Isotope labeling of protein hydrolysates by U-^13^C- glucose in organoid-PSC co-cultures after sorting.](elife-56782-fig4){#fig4}

Because the labeling of amino acids in protein is unlikely to reach steady-state even after multiple days of labeling, one explanation for the difference in aspartate labeling from labeled glucose in the cancer cells relative to the PSCs is a higher rate of protein synthesis in the cancer cells, although this is unlikely to differentially affect only M+3 labeled species. Nevertheless, to examine this possibility, we measured protein synthesis rates in each cell type using a fluorescent protein synthesis reporter in which BFP is fused to an unstable *E. coli* dihydrofolate reductase (DHFR) domain. Upon addition of the DHFR active site ligand trimethoprim (TMP), the reporter is stabilized and the rate of fluorescence accumulation reflects the synthesis rate of the fluorescent protein ([@bib35]). Consistent with previous reports, this reporter produced similar results compared to an assessment of protein synthesis through incorporation rates of the aminoacyl tRNA analog puromycin ([@bib22]) when BFP accumulation after TMP addition was assayed over time in PDAC cancer cell and PSC mono-cultures and compared to cells with no TMP added as a negative control ([Figure 4---figure supplement 1F--G](#fig4s1){ref-type="fig"}). The BFP reporter is suitable for use in sorted cells from a mixed cell system, and thus was used to assess protein synthesis rates in cancer cells and PSCs in organoid co-cultures. Interestingly, even though cancer cells and PSCs exhibited a similar protein synthesis rate in monoculture ([Figure 4---figure supplement 1F--G](#fig4s1){ref-type="fig"}), accumulation of BFP fluorescence was slower in cancer cells compared to PSCs in 3D co-cultures ([Figure 4H](#fig4){ref-type="fig"}). This argues that protein synthesis rates are higher in PSCs in organoid co-cultures, and that the higher M+3 aspartate labeling observed in cancer cells cannot be explained by a higher rate of protein synthesis in the cancer cells in this co-culture system.

M+3 labeling from U-^13^C-glucose is often used as a surrogate for pyruvate carboxylation activity, but can also occur from multiple rounds of TCA cycling ([@bib2]). To more directly assess pyruvate carboxylation activity in additional experiments with multiple replicates, we traced 1-^13^C-pyruvate or 3,4-^13^C-glucose fate in organoid-PSC co-cultures. 1-^13^C-pyruvate or 3,4-^13^C-glucose can only label aspartate via pyruvate carboxylation, because the ^13^C-label is lost as carbon dioxide if pyruvate is metabolized to acetyl-coA via PDH prior to entering the TCA cycle ([Figure 4I](#fig4){ref-type="fig"}). Compared to U-^13^C-glucose labeling, a greater difference and significantly higher M+1 aspartate labeling in protein was observed using 1-^13^C-pyruvate or 3,4-^13^C-glucose in sorted cancer cells compared to PSCs from organoid-PSC co-cultures, further supporting that pyruvate carboxylation activity is higher in these cells ([Figure 4J--K](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1H](#fig4s1){ref-type="fig"}). Taken together, these data argue that cancer cells within PDAC organoid-PSC co-cultures have higher pyruvate carboxylation activity than PSCs.

To investigate whether PDAC cancer cells also exhibit higher pyruvate carboxylation activity in tumors in vivo, we first verified that the tdTomato fluorescence in tumors arising in KP^-/-^C mice bearing a *LSL-tdTomato* allele did not co-localize with staining for the fibroblast-specific marker alpha-smooth muscle actin (α-SMA) ([Figure 5A](#fig5){ref-type="fig"}), but did co-localize with Cytokeratin 19 (CK19), a marker of pancreatic cancer cells ([Figure 5B](#fig5){ref-type="fig"}). This verifies that tdTomato labeling can be used to isolate cancer cells from α-SMA-positive fibroblasts, and a combination of tdTomato fluorescence and an antibody for the pan-hematopoietic marker CD45 allowed efficient sorting of cancer cells, fibroblasts, and hematopoietic cells as verified by expression of relevant mRNAs using qPCR ([Figure 5C--F](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A--B](#fig5s1){ref-type="fig"}). To label protein in PDAC tumors in vivo, autochthonous tumor-bearing mice were infused with U-^13^C-glucose for 24 hr ([Figure 5---figure supplement 1C--D](#fig5s1){ref-type="fig"}), with aspartate labeling observed in protein hydrolysates from bulk tumors in this time frame ([Figure 5G](#fig5){ref-type="fig"}). Cell populations were sorted from tumors, and labeling of amino acids was determined in protein hydrolysates from each cell population as well as from protein obtained from the bulk digested tumor (unsorted). In agreement with labeling patterns from organoid-co-cultures, tdTomato^+^ cancer cells from PDAC tumors in mice had the highest M+3 protein aspartate labeling in protein, as well as higher M+2 aspartate labeling ([Figure 5H--I](#fig5){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). This labeling pattern was also reflected in higher M+2 and M+3 labeling in glutamate but not in other glucose-labeled amino acids in protein ([Figure 5---figure supplement 1E--J](#fig5s1){ref-type="fig"}, [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Taken together, these data are consistent with increased pyruvate carboxylation, as well as increased glucose oxidation via PDH, in the cancer cells relative to the stromal cell populations analyzed in PDAC tumors in vivo.

![PDAC cancer cells have higher pyruvate carboxylation activity in vivo.\
(**A--B**) Tumors from *LSL-Kras^G12D/+^; Trp53^fl/fl^; Pdx1-Cre; LSL-tdTomato* (KP^-/-^CT) mice were stained with antibodies against RFP (red) and (**A**) α-SMA (green), a fibroblast marker, or (**B**) CK19 (green), a cancer cell marker. Scale bars represent 25 μm. (**C**) A representative flow cytometry plot showing CD45 and tdTomato expression in cells derived from a PDAC tumor arising in KP^-/-^CT mice. Cells were gated on the live population. (**D**) Expression of tdTomato was measured by qPCR in sorted cells from KP^-/-^CT PDAC tumors. The difference in expression between cancer cells and whole tumor (p=0.0430), fibroblasts (p=0.0156), or hematopoietic cells (p=0.0119) was significant based on unpaired, two-tailed student's t-tests. Mean +/- SEM is shown. n = 6 mice. 18S was used as a housekeeping gene control. (**E**) Expression of α-SMA was measured by qPCR in sorted cells from KP^-/-^CT PDAC tumors. The difference in expression between fibroblasts and whole tumor (p=0.0004), cancer cells (p=0.0013), or hematopoietic cells (p=0.0003) was significant based on unpaired, two-tailed student's t-tests. Mean +/- SEM is shown. n = 6 mice. 18S was used as a housekeeping gene control. (**F**) Expression of CD3ε was measured by qPCR in sorted cells from KP^-/-^CT PDAC tumors. The difference in expression between hematopoietic cells and whole tumor was not significant (p=0.3347), but the difference between hematopoietic cells and cancer cells (p=0.0378) or fibroblasts (p=0.0379) was significant based on unpaired, two-tailed student's t-tests. Mean +/- SEM is shown. n = 6 mice. 18S was used as a housekeeping gene control. (**G**) Fractional labeling of aspartate from protein hydrolysates from intact PDAC tumors following a 24 hr U-^13^C-glucose infusion at a rate of 30 mg/kg/min. n = 4. Mean +/- SEM is shown. (**H**) Fractional labeling of aspartate from protein hydrolysates from the indicated sorted cell populations from tumors arising in KP^-/-^CT mice following a 24 hr U-^13^C-glucose infusion at a rate of 30 mg/kg/min. The M+3 isotopomers are shown. The differences in M+3 aspartate labeling in cancer cells compared to fibroblasts (p=0.0413) and hematopoietic cells (p=0.0005) were significant, and the difference between cancer cells and unsorted tumor cells (p=0.0612) was not significant based on unpaired, two-tailed student's t-tests. Mean +/- SEM is shown. n = 5 mice. (**I**) Fractional labeling of aspartate from protein hydrolysates from the indicated sorted cell populations from tumors arising in KP^-/-^CT mice following a 24 hr U-^13^C-glucose infusion at a rate of 30 mg/kg/min. The M+2 isotopomers are shown. The differences in M+2 aspartate labeling in cancer cells compared to fibroblasts (p=0.0309) and hematopoietic cells (p=0.0035) were significant, and the difference between cancer cells and unsorted tumor cells (p=0.7444) was not significant based on unpaired, two-tailed student's t-tests. Mean +/- SEM is shown. n = 5 mice.\
Figure 5---source data 1.Isotope labeling of protein hydrolysates in mice with autochthonous PDAC tumors after 24 hr of U-^13^C- glucose infusion and sorting.](elife-56782-fig5){#fig5}

Pyruvate carboxylase expression in cancer cells is required for PDAC tumor growth in vivo {#s2-5}
-----------------------------------------------------------------------------------------

To test whether PC is responsible for the observed pyruvate carboxylation activity and is functionally important for cells to proliferate in organoid co-cultures and tumors, PC expression was disrupted in murine PDAC cell lines, organoids, and PSCs using CRISPR/Cas9. First, CRISPRi was used to knock down PC expression in a PDAC cancer cell line derived from KP^-/-^C mice ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}; [@bib39]). The ratio of M+1 aspartate to M+1 pyruvate derived from 1-^13^C-pyruvate or 3,4-^13^C-glucose has been used as a way to approximate pyruvate carboxylation activity ([@bib23]). As expected, PC knockdown in these PDAC cells resulted in a decrease in aspartate labeling from 1-^13^C-pyruvate and relative pyruvate carboxylation activity compared to control cells as assessed by the ratio of M+1 labeled aspartate to M+1 labeled pyruvate ([Figure 6---figure supplement 1B--C](#fig6s1){ref-type="fig"}), but did not affect proliferation in culture ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). However, knockdown of PC in PDAC organoids reduced growth of these cells in organoid-PSC co-cultures ([Figure 6---figure supplement 1E--G](#fig6s1){ref-type="fig"}). PC expression level and aspartate labeling from 1-^13^C-pyruvate were increased by exogenous PC expression in PDAC PC knockdown cells ([Figure 6---figure supplement 1H--J](#fig6s1){ref-type="fig"}). When transplanted subcutaneously, PDAC cell lines with PC knockdown formed tumors that grew similarly to control cells ([Figure 6---figure supplement 1K](#fig6s1){ref-type="fig"}); however, PC expression was similar or increased in the tumors formed from PC knockdown cells compared to control tumors ([Figure 6---figure supplement 1L](#fig6s1){ref-type="fig"}). These data suggest that over time, cells that grew into tumors were selected for reversal of PC knockdown and that PC is required for PDAC tumor growth in vivo even though it is dispensable in culture, as has been observed previously in lung cancer ([@bib23]; [@bib26]; [@bib75]).

To further test the requirement for PC in PDAC tumors, we generated cancer cell clones with complete CRISPR/Cas9 disruption of PC expression ([Figure 6---figure supplement 1M--N](#fig6s1){ref-type="fig"}). Similar to knockdown experiments, loss of PC had no effect on proliferation of PDAC cells in culture ([Figure 6A](#fig6){ref-type="fig"}), whereas loss of PC reduced the growth of organoid co-cultures ([Figure 6B--C](#fig6){ref-type="fig"}). CRISPR/Cas9 was also used to knockout PC in PSCs, and despite loss of PC expression and reduced pyruvate carboxylation activity ([Figure 6---figure supplement 2A--C](#fig6s2){ref-type="fig"}), PC knockout PSCs retained the ability to enhance PDAC organoid growth or growth of PDAC cancer cells as tumors in subcutaneous transplants, although the effect was reduced compared to sgControl PSCs ([Figure 6---figure supplement 2D--F](#fig6s2){ref-type="fig"}). Consistent with a requirement for PC expression in cancer cells to form PDAC tumors, PC-null cancer cells did not form tumors when transplanted into syngeneic mice subcutaneously or orthotopically ([Figure 6D--E](#fig6){ref-type="fig"}). However, surprisingly, PC-null cancer cells still displayed M+1 aspartate labeling from 1-^13^C-pyruvate with similar or only a slight decrease in pyruvate carboxylation activity compared to control cells ([Figure 6F--G](#fig6){ref-type="fig"}). Taken together, these data argue that loss of PC in cancer cells can impact tumor growth, but another enzyme must also contribute to pyruvate carboxylation activity in these cells.

![Pyruvate carboxylase in cancer cells is required for PDAC tumor growth in vivo.\
(**A**) Proliferation rate of AL1376 murine PDAC cells without (sgControl) or with (sgPC) deletion in standard 2D culture. Mean +/- SD is shown. (**B**) Fluorescent images of murine PDAC cancer cell organoids expressing tdTomato without (sgControl) or with (sgPC) deletion cultured in DMEM-pyruvate with 10% dialyzed FBS alone (top) or with murine PSCs (bottom). (**C**) Quantification of tdTomato fluorescence from images in (**B**). Control organoids with PSCs had significantly higher tdTomato fluorescence than sgPC organoids grown with PSCs (p=0.0171) based on an unpaired, two-tailed student's t-test. Mean +/- SD is shown. (**D**) Growth of sgControl (black) and sgPC (blue) AL1376 murine PDAC cells as tumors following subcutaneous transplantation into syngeneic Bl6 mice. The final tumor volume is significantly greater in sgControl AL1376 cells compared to sgPC cells based on unpaired, two-tailed student's t-tests (p\<0.0001 to 0.0049). Mean +/- SEM is shown. n = 6 for each group. (**E**) Growth of sgControl and sgPC AL1376 murine PDAC cells as tumors after orthotopic transplantation into the pancreas of syngeneic Bl6 mice. Tumor weight was measured after 21 days and was significantly greater in mice transplanted with sgControl cells based on an unpaired, two-tailed student's t-test (p=0.0050). Mean +/- SEM is shown. n = 5 mice for each group. (**F**) Fractional labeling of aspartate in sgControl and sgPC AL1376 murine PDAC cells after 24 hr of culture with 1-^13^C-pyruvate. Mean +/- SD is shown. (**G**) Aspartate M+1 isotopomer labeling from (**F**) was normalized to pyruvate M+1 labeling as a surrogate for pyruvate carboxylation activity. Mean +/- SD is shown.](elife-56782-fig6){#fig6}

Reversible malic enzyme 1 activity contributes to pyruvate carboxylation activity in PDAC cells and is important for tumor growth in vivo {#s2-6}
-----------------------------------------------------------------------------------------------------------------------------------------

A candidate for the pyruvate carboxylation activity observed in PC-null cells is malic enzyme, since this enzyme catalyzes the interconversion of pyruvate and CO~2~ with malate, another 4-carbon TCA cycle intermediate. Malic enzyme is typically assumed to catalyze malate decarboxylation as a source of NADPH in cells ([@bib13]; [@bib41]), but has previously been shown to be reversible and produce malate from pyruvate and CO~2~ in purified enzyme assays ([@bib62]; [@bib63]). Thus, we tested whether malic enzyme activity could sustain M+1 labeling of aspartate in PDAC cancer cells lacking PC by using CRISPR/Cas9 to knock out malic enzyme 1 (ME1). After knockout of both PC and ME1 in PDAC cell lines, aspartate labeling from 1-^13^C-pyruvate is virtually abolished, suggesting that ME1 activity can contribute to pyruvate carboxylation activity in these cells ([Figure 7A--B](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). This aspartate labeling was also increased after exogenous expression of ME1 in PC and ME1 double knockout cells ([Figure 7A--B](#fig7){ref-type="fig"}). We used CRISPR/Cas9 to knockout or knockdown both PC and ME1 in organoids, which also resulted in decreased M+1 aspartate labeling from 1-^13^C-pyruvate and decreased pyruvate carboxylation activity ([Figure 7---figure supplement 1B--D](#fig7s1){ref-type="fig"}). We also used CRISPR/Cas9 to knockout ME1 alone in PDAC cell lines and organoids ([Figure 7---figure supplement 1E--H](#fig7s1){ref-type="fig"}). Reduction or loss of ME1 alone in PDAC cell lines resulted in lower aspartate M+1 labeling and pyruvate carboxylation activity from 1-^13^C-pyruvate ([Figure 7---figure supplement 1F--K](#fig7s1){ref-type="fig"}), further suggesting a role for ME1 in anaplerosis. This aspartate labeling was also increased after exogenous expression of ME1 in ME1 knockdown cells ([Figure 7---figure supplement 1L--N](#fig7s1){ref-type="fig"}). Interestingly, ME1 expression in KP^-/-^C mouse and human PDAC tumors and organoids mimics that of PC in that it is more highly expressed in cancer cells compared to stroma, suggesting that ME1 could also contribute to the higher pyruvate carboxylation seen in cancer cells compared to PSCs ([Figure 7C--E](#fig7){ref-type="fig"}, [Figure 7---figure supplement 2A--E](#fig7s2){ref-type="fig"}).

![Malic enzyme 1 contributes to pyruvate carboxylation activity in PDAC cells and is important for tumor growth.\
(**A--B**) CRISPR/Cas9 was used to disrupt PC and/or ME1 as indicated in AL1376 murine PDAC cells. (**A**) Fractional labeling of M+1 aspartate following culture of the indicated cells for 24 hr in media containing 1-^13^C-pyruvate. M+1 aspartate labeling was significantly decreased in double knockout cells compared to control cells (p=0.0012, 0.0001, and 0.0131) or to double knockout cells with exogenous ME1 expression (ME rescue) (p=0.0006) based on unpaired, two-tailed student's t-tests. Mean +/- SD is shown. (**B**) Aspartate M+1 isotopomer labeling was normalized to pyruvate M+1 labeling as a surrogate for pyruvate carboxylation activity following 24 hr of 1-^13^C-pyruvate tracing. Pyruvate carboxylation activity was significantly decreased in double knockout cells compared to control cell lines (p=0.0004, 0.0002, and 0.0100) or to double knockout cells with exogenous ME1 expression (ME rescue) (p\<0.0001) based on unpaired, two-tailed student's t-tests. Mean +/- SD is shown. (**C**) Sections from tumors arising in *LSL-Kras^G12D/+^; Trp53^fl/fl^; Pdx1-Cre* (KP^-/-^C) mice were stained with an antibody against ME1. Scale bar represents 100 μm. (**D**) Expression of ME1 was measured by qPCR in the indicated cells sorted from tumors arising in KP^-/-^C mice. The expression of ME1 was not significantly different in sorted cancer cells compared to the whole tumor (p=0.1114), but was significantly higher in sorted cancer cells compared to fibroblasts (p=0.0009) based on unpaired, two-tailed student's t-tests. Mean +/- SEM is shown. 36B4 was used as a housekeeping gene control. (**E**) Representative image from a human pancreatic tumor tissue microarray stained with an antibody against ME1. Scale bar represents 100 μm. (**F**) Proliferation rate of sgControl and sgME1 AL1376 murine PDAC cells in standard 2D culture. (**G**) Quantification of tdTomato fluorescence from images of sgControl or sgME1 PDAC cancer cell organoids isolated from KP^-/-^CT tumors cultured in DMEM-pyruvate with 10% dialyzed FBS alone or with murine PSCs. sgControl organoids with PSCs trended towards higher tdTomato fluorescence compared to sgME1 organoids with PSCs (p=0.0579) but was not significant based on an unpaired, two-tailed student's t-test. Mean +/- SD is shown. The sgControl data are also shown in [Figure 6B--C](#fig6){ref-type="fig"}. (**H**) Fluorescent images of sgControl or sgME1 PDAC cancer cell organoids cultured DMEM-pyruvate with 10% dialyzed FBS alone (top) or with murine PSCs (bottom). The sgControl images are also shown in [Figure 6B--C](#fig6){ref-type="fig"}. (**I**) Growth of sgControl (black) and sgME1 (blue) AL1376 murine PDAC cells as tumors following subcutaneous transplantation into syngeneic B6 mice. The final tumor volume is significantly greater in sgControl AL1376 cells compared to sgME1 cells based on unpaired, two-tailed student's t-tests (p\<0.0001 to 0.0017). Mean +/- SEM is shown. n = 6 for each group.](elife-56782-fig7){#fig7}

We next assessed whether ME1 was essential for tumor and organoid growth. Similar to loss of PC, loss of ME1 had minimal effect on cancer cell proliferation in monoculture ([Figure 7F](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1F](#fig7s1){ref-type="fig"}), but reduced growth of organoid co-cultures compared to controls ([Figure 7G--H](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Transplantation of ME1-null cancer cells in vivo also resulted in reduced tumor growth ([Figure 7I](#fig7){ref-type="fig"}), consistent with published data ([@bib79]). Taken together, these data argue that both PC and ME1 are important enzymes for PDAC cancer cells in tumors and can contribute to the pyruvate carboxylation activity observed in pancreatic cancer.

Discussion {#s3}
==========

Metabolism can differ between cancer cells in culture and tumors, and understanding how nutrients are used by cancer cells in vivo has been an area of interest for developing cancer therapies. Tumor metabolic phenotypes have been assumed to reflect the metabolism of cancer cells within a tumor; however, in many tumors such as in PDAC, cancer cells are a minority cell population. Metabolic interactions between cell types have been described in normal tissues ([@bib7]), and some metabolic phenotypes observed in cancer cells such as increased glucose utilization are also prominent in other cell types including fibroblasts and immune cells that can be abundant in some tumors ([@bib47]; [@bib89]; [@bib97]). Therefore, methods to deconvolute which cell types in a tumor are responsible for observed tissue metabolic phenotypes are needed.

We find that pancreatic tumors exhibit evidence of glucose metabolism, with carboxylation of glucose-derived pyruvate being more active in cancer cells than in other tumor cell types. However, because glucose will label both pyruvate and lactate, and these nutrients can be exchanged between cell types, it cannot be concluded that the cancer cells necessarily derive TCA cycle metabolites directly from glucose in a cell autonomous manner. In fact, rapid exchange of labeled intracellular and extracellular pyruvate and lactate among cell types is likely, making it difficult to address the original cellular source of labeled TCA metabolites with these methods. Thus, while this approach could be used to understand differential pathway use between cell types, in many cases it will not be able to distinguish the exact source of carbon that labels metabolites in individual cells.

Another important caveat to interpreting labeling patterns in protein or other macromolecules in cells within tissues is that labeling is unlikely to reach steady state, particularly for analysis of cells in tissues in vivo. This failure to reach steady state means that differences in label delivery or uptake could cause differences in biomass labeling even when the pathway involved in labeling is similarly active in both cell types. Thus, controlling for variables such as biomass synthesis rates between cell types can help with data interpretation. The ability to reach a pseudo-metabolic steady state facilitates interpretation of labeling data; however, this requires that both circulating nutrient levels and labeling patterns are relatively constant ([@bib11]; [@bib44]). Glucose infusion rates and techniques can vary across studies ([@bib23]; [@bib27]; [@bib43]; [@bib53]; [@bib54]), and these differences may affect whether circulating nutrient levels are constant. While this may be one reason why differences in labeling were observed across PDAC models evaluated in this study, additional factors such as tumor initiation and growth rates, cells of origin, p53 status, and different composition of cancer and stromal cells are known to exist as well ([@bib70]; [@bib87]).

While we did not directly assess the effects of cell sorting on metabolite levels or labeling in this study, we observed that for some metabolites, their levels and/or labeling patterns are not stable over the time needed to sort cells. However, the labeling patterns of some metabolites were maintained despite changes in levels, and might still be used to derive information about cell-specific metabolism, particularly when appropriate controls and orthogonal evidence support the conclusions.

We find that whether cells are grown in 2D cultures, in 3D organoid co-culture with PSCs, or as orthotopic or subcutaneous tumors impacts whether pyruvate carboxylation is important for proliferation, with the organoid and tumor models showing a similar dependency on this activity. Tumor organoid-stromal co-cultures represent a tractable model for metabolic characterization, and thus may be useful for exploration of other symbiotic metabolic relationships between pancreatic cancer cells and fibroblasts. However, while the difference in M+3 aspartate labeling seen in vivo was recapitulated by organoid-fibroblast co-cultures, other differences such as higher M+2 aspartate and glutamate labeling observed in vivo were not observed in the co-culture model. Therefore, some aspects of cell type-specific metabolism are not recapitulated even in co-culture organoid systems.

We find that PC and ME1 expression in cancer cells are both important for PDAC tumor growth in vivo. A dependence on pyruvate carboxylation seems to be a characteristic of both PDAC and lung tumors in vivo that is not prominent in standard cell culture systems ([@bib18]; [@bib23]; [@bib26]; [@bib36]; [@bib75]). Why this is the case is not known, but PC is an important anaplerotic pathway for the TCA cycle, contributing to biosynthesis of macromolecules such as protein, nucleotides, and lipids in cancer cells. Glucose metabolism and increased glucose uptake have been shown to be important for biosynthesis in PDAC tumors ([@bib73]; [@bib93]), but it has also been suggested that some PDAC tumors rely less on glucose for fuel and instead on alternative nutrient sources such as circulating lactate and glutamine ([@bib43]), or alanine from stromal autophagy ([@bib80]). We did not observe differences in protein alanine labeling from glucose in either PSCs or organoids, although it remains possible the cells differentially utilize alanine acquired from a source other than glucose. For example, macropinocytosis to catabolize extracellular protein can be an important source of amino acids for cells in PDAC tumors ([@bib19]; [@bib24]). Nevertheless, the findings that PDAC tumors are FDG-PET positive ([@bib61]; [@bib66]; [@bib92]) and that levels of glucose are depleted in tumor interstitial fluid relative to plasma in PDAC mouse models ([@bib82]), are consistent with glucose being consumed by at least some cell types within the tumor.

Glutamine is also a source of TCA anaplerotic carbon that may contribute to biosynthesis differentially between cancer cells and stroma. Previous work has suggested that utilization of ME1 to produce pyruvate from glutamine can be important for PDAC cells to maintain redox balance, specifically via NADPH generation in vitro ([@bib79]), and that glutamine can be a major contributor to TCA metabolites in PDAC tumors ([@bib43]). A potential role for malic enzyme in pyruvate carboxylation suggests use of this enzyme to produce malate could be another pathway for TCA cycle anaplerosis. Of note, this reaction would require NADPH, and may be more favored in cancer cells that exhibit a reduced redox state ([@bib41]). Furthermore, other pathways produce NADPH in cancer cells, including the pentose phosphate pathway, the one-carbon cycle, or isocitrate dehydrogenase ([@bib17]). We also considered phosphoenolpyruvate carboxykinase (PEPCK) or malic enzymes 2 and 3 as possible contributors to pyruvate carboxylation activity, although these reactions are less energetically favorable in the reverse direction in comparison to malic enzyme 1; malic enzyme 1 is cytosolic, which is thought to be a more reducing environment than the mitochondria where malic enzymes 2 and 3 are localized ([@bib42]). We did not see evidence for differential glutamine utilization in our organoid-PSC co-cultures, and PDAC tumors are resistant to glutaminase inhibitors ([@bib8]), but further work is needed to assess how glutamine metabolism and other anaplerotic pathways might be differentially active in cancer cells and non-cancer cells in PDAC tumors.

In pancreatic β-cells, PC and ME are thought to be part of a coordinated metabolic cycle that regulates insulin secretion ([@bib68]). In this pyruvate cycle, ME1 generates NADPH and produces pyruvate from malate in the cytosol, which can then be used by PC to generate oxaloacetate in the mitochondria ([@bib68]). While loss of ME activity might be expected to impact pyruvate carboxylation activity when both enzymes are present, the fact that residual pyruvate carboxylation activity is observed in the absence of PC, and that this is lost upon ME1 disruption argues that PC and ME may have redundant metabolic functions under some conditions. Surprisingly, isotope labeling in cells with loss of ME1 alone showed a larger decrease in labeling consistent with pyruvate carboxylation than was observed with PC knocked out and ME1 left intact. However, these data should not be used to conclude that flux through ME1 is higher than PC, particularly in cells where both enzymes are expressed and pyruvate cycling can occur. PC and ME1 are each essential for pancreatic tumors in vivo, despite a possible redundancy in pyruvate carboxylation activity. This may be because pyruvate cycling is important for tumor growth, or the need for anaplerosis to support tumor growth is more constrained in tumors than in cell culture. Indeed, a dependence on pyruvate carboxylation seems to be a characteristic of tumors in vivo that is not observed in culture across many cancer models ([@bib18]; [@bib23]; [@bib26]; [@bib36]; [@bib75]).

PC has been targeted with antisense oligonucleotides ([@bib45]) and relatively non-specific chemical inhibitors ([@bib4]; [@bib96]); however, inhibiting PC may have deleterious effects on whole body metabolism by interfering with gluconeogenesis or glucose-stimulated insulin secretion. Whether malic enzyme can compensate sufficiently for PC inhibition in those tissues to allow therapeutic targeting, or if malic enzyme is a viable alternative target, remains to be determined. Nevertheless, our data suggest that stable isotope tracing into macromolecules can be utilized to deconvolute complex tracing patterns in mammalian tissues and identify increased pathway activity in a particular cell type. Understanding the metabolic similarities and differences between cancer cells and stroma within PDAC and other tumors will be important in further delineating cancer-specific dependencies.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                  Designation                                                                                       Source or\                                                   Identifiers                                                                                Additional\
  (species) or\                                                                                                                    reference                                                                                                                                               information
  resource                                                                                                                                                                                                                                                                                 
  ------------------------------ ------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------
  Strain, strain background\     C57Bl6/J                                                                                          Jax                                                          Cat\# JAX:000664, RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)   Used for cell line transplantation
  (*Mus musculus*)                                                                                                                                                                                                                                                                         

  Genetic Reagent\               *LSL-Kras^G12D/+^*\                                                                               [@bib6]\                                                                                                                                                Mice from a mixed 129/Sv and C57Bl6/J genetic background as well as pure C57Bl6/J mice were used. Both sexes of mice were included in experiments.
  (*M. musculus*)                *Trp53*^flox/flox^\                                                                               PMID:[16585505](https://pubmed.ncbi.nlm.nih.gov/16585505/)                                                                                              
                                 *Pdx-1-Cre*\                                                                                                                                                                                                                                              
                                 *LSL-tdTomato;*\                                                                                                                                                                                                                                          
                                 KP^-/-^CT                                                                                                                                                                                                                                                 

  Genetic Reagent\               *LSL-Kras^G12D/+^*\                                                                               [@bib37]\                                                                                                                                               Mice from a mixed 129/Sv and C57Bl6/J genetic background as well as pure C57Bl6/J mice were used. Both sexes of mice were included in experiments.
  (*M. musculus*)                *Trp53*^R172H/+^\                                                                                 PMID:[15894267](https://pubmed.ncbi.nlm.nih.gov/15894267/)                                                                                              
                                 *Pdx-1-Cre*\                                                                                                                                                                                                                                              
                                 *LSL-tdTomato*;\                                                                                                                                                                                                                                          
                                 KPCT                                                                                                                                                                                                                                                      

  Genetic Reagent\               *β-actin-GFP*                                                                                     Jax                                                          Cat\# JAX:006567, RRID:[IMSR_JAX:006567](https://scicrunch.org/resolver/IMSR_JAX:006567)   PSCs were isolated from *β-actin-GFP* mice in a C57Bl6/J background.
  (*M. musculus*)                                                                                                                                                                                                                                                                          

  Cell line\                     PSC                                                                                               [@bib21]\                                                                                                                                               Isolated from *β-actin-GFP* mice in a C57Bl6/J background (Jax 006567). PSCs were immortalized with TERT and SV40 largeT after several passages.
  (*M. musculus*)                                                                                                                  PMID:[29925948](https://pubmed.ncbi.nlm.nih.gov/29925948/)                                                                                              

  Cell line\                     AL1376                                                                                            [@bib81]\                                                                                                                                               Isolated from KP^-/-^CT mouse PDAC tumor in a C57Bl6/J background.
  (*M. musculus*)                                                                                                                  PMID:[29941931](https://pubmed.ncbi.nlm.nih.gov/29941931/)                                                                                              

  Cell line\                     Organoid                                                                                          This paper                                                                                                                                              Isolated from KP^-/-^CT mouse PDAC tumor in a C57Bl6/J background
  (*M. musculus*)                                                                                                                                                                                                                                                                          

  Biological sample\             Human pancreatic cancer tissue microarray                                                         Biomax                                                       PA961e                                                                                     
  (*Homo sapiens*)                                                                                                                                                                                                                                                                         

  Antibody                       α-SMA (mouse monoclonal)                                                                          Sigma                                                        Cat\# F3777, RRID:[AB_476977](https://scicrunch.org/resolver/AB_476977)                    IF (1:500)

  Antibody                       CK19\                                                                                             Abcam                                                        Cat\# ab133496,\                                                                           IF (1:100)
                                 (Rabbit monoclonal)                                                                                                                                            RRID:[AB\_ 11155282](https://scicrunch.org/resolver/AB_11155282)                           

  Antibody                       tdTomato (Rabbit polyclonal)                                                                      Rockland                                                     Cat\# 600-401-379, RRID:[AB_2209751](https://scicrunch.org/resolver/AB_2209751)            IF (1:500)

  Antibody                       Pyruvate Carboxylase\                                                                             Santa Cruz                                                   Cat\# sc-67021, RRID:[AB_2283532](https://scicrunch.org/resolver/AB_2283532)               IHC (1:50)
                                 (Rabbit polyclonal)                                                                                                                                                                                                                                       

  Antibody                       Pyruvate Carboxylase\                                                                             Santa Cruz                                                   Cat\# sc-271493, RRID:[AB_10649369](https://scicrunch.org/resolver/AB_10649369)            WB (1:100)
                                 (Mouse monoclonal)                                                                                                                                                                                                                                        

  Antibody                       Malic Enzyme 1 (Rabbit polyclonal)                                                                Proteintech                                                  Cat\# 16619-1-AP, RRID:[AB_2143821](https://scicrunch.org/resolver/AB_2143821)             IHC (1:200)\
                                                                                                                                                                                                                                                                                           WB (1:250)

  Antibody                       β-actin (Rabbit monoclonal)                                                                       Cell Signaling Technologies                                  Cat\# 8457, RRID:[AB_10950489](https://scicrunch.org/resolver/AB_10950489)                 WB (1:10,000)

  Antibody                       CD16/CD32 (Rat monoclonal)                                                                        Thermo Fisher                                                Cat\# 14-0161-82, RRID:[AB_467133](https://scicrunch.org/resolver/AB_467133)               FACS (10uL)

  Antibody                       CD45-APC-Cy7\                                                                                     BD                                                           Cat\# 557659, RRID:[AB_396774](https://scicrunch.org/resolver/AB_396774)                   FACS (1:100)
                                 (Rat monoclonal)                                                                                                                                                                                                                                          

  Antibody                       Puromycin\                                                                                        Sigma                                                        MABE343                                                                                    WB (1:25,000)
                                 (Mouse monoclonal)                                                                                                                                                                                                                                        

  Antibody                       Vinculin\                                                                                         Abcam                                                        Cat\# ab18058, RRID:[AB_444215](https://scicrunch.org/resolver/AB_444215)                  WB (1:1000)
                                 (Mouse monoclonal)                                                                                                                                                                                                                                        

  Commercial Assay or Kit        Protein A Antibody Purification Kit                                                               Sigma                                                        PURE1A                                                                                     

  Commercial Assay or Kit        RNAqueous-Micro Total RNA Isolation Kit                                                           Life Technologies                                            AM1931                                                                                     

  Commercial Assay or Kit        iScript cDNA Synthesis Kit                                                                        Bio-Rad Laboratories                                         1708890                                                                                    

  Commercial Assay or Kit        Pierce BCA Protein Assay Kit                                                                      Pierce                                                       23225                                                                                      

  Commercial Assay or Kit        Amaxa Basic Nucleofector Kit for Primary Mammalian Epithelial Cells                               Amaxa                                                        VPI-1005                                                                                   

  Recombinant DNA Reagent        pUSPmNG (plasmid)                                                                                 [@bib49]\                                                                                                                                               U6 sgRNA PGK with mNeonGreen to express sgRNAs for PC and ME1 double knockout cell lines
                                                                                                                                   PMID:[31694929](https://pubmed.ncbi.nlm.nih.gov/31694929/)                                                                                              

  Recombinant DNA Reagent        LentiCRISPRv2 (plasmid)                                                                           [@bib72]\                                                                                                                                               Lentiviral construct to create PC and ME1 knockout cells
                                                                                                                                   PMID:[25075903](https://pubmed.ncbi.nlm.nih.gov/25075903/)                                                                                              

  Recombinant DNA Reagent        Modified LentiCRISPRv2 (plasmid)                                                                  [@bib39]\                                                                                                                                               Modified dCas9-KRAB fusion protein to create PC and ME1 knockdown cells
                                                                                                                                   PMID:[27661255](https://pubmed.ncbi.nlm.nih.gov/27661255/)                                                                                              

  Recombinant DNA Reagent        pLV-Hygro-EFS\                                                                                    Vectorbuilder                                                                                                                                           Custom lentiviral construct for re-expressing PC or ME1 cDNA under a CMV promoter
                                 (plasmid)                                                                                                                                                                                                                                                 

  Peptide, recombinant protein   EGF                                                                                               Thermo Fisher                                                PMG8041                                                                                    

  Peptide, recombinant protein   FGF                                                                                               Peprotech                                                    100-26                                                                                     

  Peptide, recombinant protein   Gastrin I                                                                                         TOCRIS                                                       3006                                                                                       

  Peptide, recombinant protein   Noggin                                                                                            Peprotech                                                    250-38                                                                                     

  Chemical compound, drug        Collagenase I                                                                                     Worthington Biochemical                                      LS004194                                                                                   

  Chemical compound, drug        Collagenase XI                                                                                    Sigma                                                        C9407                                                                                      

  Chemical compound, drug        Collagenase P                                                                                     Sigma                                                        11213865001                                                                                

  Chemical compound, drug        Dispase II                                                                                        Roche                                                        04942078001                                                                                

  Chemical compound, drug        TrypLE Express                                                                                    Thermo Fisher                                                12605-010                                                                                  

  Chemical compound, drug        DNAse I\                                                                                          Sigma                                                        D4527                                                                                      
                                 Type II                                                                                                                                                                                                                                                   

  Chemical compound, drug        DNAse I\                                                                                          Sigma                                                        D5025                                                                                      
                                 Type IV                                                                                                                                                                                                                                                   

  Chemical compound, drug        GlutaMAX                                                                                          Thermo Fisher                                                35050                                                                                      

  Chemical compound, drug        HEPES                                                                                             Thermo Fisher                                                15630                                                                                      

  Chemical compound, drug        TGF-b inhibitor\                                                                                  TOCRIS                                                       2939                                                                                       
                                 A-83-01                                                                                                                                                                                                                                                   

  Chemical compound, drug        Rho Kinase Inhibitor Y-27632                                                                      Sigma                                                        Y0503                                                                                      

  Chemical compound, drug        N-Acetylcysteine (NAC)                                                                            Sigma                                                        A9165                                                                                      

  Chemical compound, drug        Nicotinamide                                                                                      Sigma                                                        N0636                                                                                      

  Chemical compound, drug        B-27 supplement                                                                                   Thermo Fisher                                                17504                                                                                      

  Chemical compound, drug        Methoxamine (MOX) reagent                                                                         ThermoFisher                                                 TS-45950                                                                                   

  Chemical compound, drug        N--methyl--N--(tert--butyldimethylsilyl)trifluoroacetamide + 1% tert--Butyldimethylchlorosilane   Sigma                                                        375934                                                                                     

  Chemical compound, drug        Pyridine                                                                                          Sigma                                                        270407                                                                                     

  Chemical compound, drug        Nycodenz                                                                                          VWR                                                          100356-726                                                                                 

  Chemical compound, drug        Sulforhodamine B                                                                                  Sigma                                                        230162                                                                                     

  Chemical compound, drug        SYBR Green Master Mix                                                                             Sigma                                                        L6544                                                                                      

  Software,\                     Prism                                                                                             GraphPad                                                                                                                                                Statistical analysis and graphing
  algorithm                                                                                                                                                                                                                                                                                

  Software, algorithm            FlowJo                                                                                            BD                                                                                                                                                      Flow cytometry data analysis

  Other                          SYTOX Red Dead Cell Stain                                                                         Life Technologies                                            S34859                                                                                     FACS (1:1000)

  Other                          Advanced DMEM/F12                                                                                 Thermo Fisher                                                12634                                                                                      

  Other                          DMEM without pyruvate                                                                             Corning                                                      10-017-CV                                                                                  

  Other                          GBSS                                                                                              Sigma                                                        G9779                                                                                      

  Other                          Growth factor reduced (GFR) matrigel                                                              Corning                                                      356231                                                                                     

  Other                          Plastic coverslips                                                                                Thermo                                                       174985                                                                                     

  Other                          Flow cytometry staining buffer                                                                    Thermo Fisher                                                00-4222-57                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse models {#s4-1}
------------

All animal studies were approved by the MIT Committee on Animal Care under protocol \#0119-001-22. For autochthonous models, *LSL-Kras^G12D/+^; Trp53*^flox/flox^*; Pdx1-Cre; LSL-tdTomato* (KP^-/-^CT) ([@bib6]) and *LSL-Kras^G12D/+^; Trp53*^R172H/+^*; Pdx1-Cre; LSL-tdTomato* (KPCT) ([@bib37]), mice from a mixed 129/Sv and C57Bl6/J genetic background as well as pure C57Bl6/J mice were used. C57Bl6/J mice were used for allografts. Both sexes of mice were included in experiments. Animals were housed under a 12 hr light and 12 hr dark cycle, and cohoused with littermates with ad libitum access to water and food unless otherwise stated.

Glucose infusion {#s4-2}
----------------

Infusion of U-^13^C-glucose (Cambridge Isotope Laboratories) was performed as previously described ([@bib23]). Surgery was performed to implant a catheter into the jugular vein of animals 3--4 days prior to infusion. For 4--6 hr infusions, mice were fasted for 4 hr prior to beginning the infusion. For 24 hr infusions, mice were not fasted prior to infusion. Infusions were performed in conscious, free-moving animals for 4 or 24 hr at a rate of 30 mg/kg/min. For 6 hr infusions, each animal, regardless of body weight, was infused with a fixed volume of 300 µl of a 500 mg/ml glucose solution over 6 hr, which is an infusion rate of 0.4 mg/min.

Tumors were either digested for FACS or rapidly frozen using a Biosqueezer (BioSpec Products) and stored at −80°C prior to metabolite extraction.

Isotope labeling experiments {#s4-3}
----------------------------

100,000 adherent cells were plated in six-well plates, or organoids and organoid-PSC co-cultures were plated on plastic coverslips (Thermo 174985) in 24-well plates. The following day, the cells were washed three times with PBS and then isotope-labeled media was added for the specified length of time (24--72 hr). For U-^13^C-glucose or 3,4-^13^C-glucose tracing, DMEM without glucose and pyruvate was used, supplemented with 25 mM U-^13^C-glucose or 3,4-^13^C-glucose, 10% dialyzed FBS, and penicillin-streptomycin. For 1-^13^C-pyruvate tracing, DMEM with glucose and without pyruvate was used, adding 2 mM 1-^13^C-pyruvate and supplementing with 10% dialyzed FBS and penicillin-streptomycin.

Polar metabolite extraction {#s4-4}
---------------------------

Adherent cells were washed once with ice-cold saline on ice and then extracted with a 5:3:5 ratio of ice-cold HPLC-grade methanol:water:chloroform. Mouse tissue or coverslips containing organoids and organoid-PSC co-cultures were washed once with saline prior to extraction. Tissue or matrigel domes containing the organoids and organoid-PSC co-cultures were then rapidly frozen using a Biosqueezer (BioSpec Products) and stored at −80°C prior to metabolite extraction. Snap frozen tissues or organoids were extracted with a 5:3:5 ratio of ice-cold HPLC-grade methanol:water:chloroform. For mouse plasma, 10 μL of plasma was extracted with 600 μL ice-cold methanol. All samples were vortexed for 10 min at 4°C followed by centrifugation for 5 min at maximum speed on a tabletop centrifuge (\~21,000 xg) at 4°C. An equal volume of the aqueous phase of each sample was then dried under nitrogen gas and frozen at −80°C until analysis. For organoid samples, two rounds of extraction were done to eliminate excess protein from matrigel.

Protein hydrolysis {#s4-5}
------------------

Acid hydrolysis of protein was performed as described previously ([@bib56]; [@bib81]). Frozen tissue or cell pellets were boiled for 24 hr at 100°C in 500 μL (cell pellets) −1 mL (tissue) 6M HCl for amino acid analysis (Sigma 84429). 50 μL (tissue) −100 μL (cell pellets) of HCl solution was then dried under nitrogen gas while heating at 80°C. Dried hydrolysates were stored at −80°C until derivatization.

GC-MS analysis {#s4-6}
--------------

Polar metabolites were analyzed as described previously ([@bib48]). Dried free metabolite extracts were dissolved in 16 μL methoxamine (MOX) reagent (ThermoFisher TS-45950) and incubated at 37°C for 90 min followed by addition of 20 μL N--methyl--N--(tert--butyldimethylsilyl)trifluoroacetamide + 1% tert--Butyldimethylchlorosilane (Sigma 375934) and incubated at 60°C for 1 hr. Dried protein hydrolysates were re-dissolved in 16 μL HPLC grade pyridine (Sigma 270407) prior to derivatization with 20 μL N--methyl--N--(tert--butyldimethylsilyl)trifluoroacetamide + 1% tert--Butyldimethylchlorosilane (Sigma 375934) at 60°C for 1 hr. Following derivatization, samples were analyzed using a DB-35MS column (Agilent Technologies) in an Agilent 7890 gas chromatograph coupled to an Agilent 5975C mass spectrometer. Helium was used as the carrier gas at a flow rate of 1.2 mL/min. One microliter of sample was injected at 270°C. After injection, the GC oven was held at 100°C for 1 min and increased to 300°C at 3.5 °C/min. The oven was then ramped to 320°C at 20 °C/min and held for 5 min. at this 320°C. The MS system operated under electron impact ionization at 70 eV and the MS source and quadrupole were held at 230°C and 150°C, respectively. The detector was used in scanning mode, and the scanned ion range was 100--650 m/z. Data were corrected for natural isotope abundance.

Adherent cell culture {#s4-7}
---------------------

Cell lines were cultured in DMEM (Corning 10--013-CV) supplemented with 10% fetal bovine serum and penicillin-streptomycin. Cell lines were regularly tested for mycoplasma contamination using the MycoAlert Plus kit (Lonza) or the Mycoprobe Mycoplasma Detection Kit (R and D Systems). PSCs were isolated from *β-actin-GFP* mice in a C57Bl6/J background (006567) as previously described ([@bib3]; [@bib21]): 3 mL of 1.3 mg/mL cold collagenase P (Sigma 11213865001) and 0.01 mg/mL DNAse (Sigma D5025) in GBSS (Sigma G9779) were injected into the pancreas. The tissue was then placed into 2 mL of collagenase P solution on ice. Cells were then placed in a 37°C water bath for 15 min. The digested pancreas was filtered through a 250 μm strainer and washed with GBSS with 0.3% BSA. A gradient was created by resuspending the cells in Nycodenz (VWR 100356--726) and layering in GBSS with 0.3% BSA. Cells were then centrifuged at 1300 x g for 20 min at 4°C. The layer containing PSCs was removed, filtered through a 70 μm strainer, washed in GBSS with 0.3% BSA, and plated for cell culture in DMEM with 10% FBS and penicillin-streptomycin. PSCs were immortalized with TERT and SV40 largeT after several passages.

Organoid culture {#s4-8}
----------------

Organoids were isolated from mice bearing PDAC tumors and cultured as previously described ([@bib10]). Tumors were minced and digested overnight with collagenase XI (Sigma C9407) and dispase II (Roche 04942078001) and embedded in 50 μL domes of growth factor reduced (GFR) matrigel (Corning 356231) covered with 500 μL of complete media. Complete media consisted of Advanced DMEM/F12 (Thermo Fisher 12634) containing GlutaMAX (Thermo Fisher 35050), penicillin-streptomycin, HEPES (Thermo Fisher 15630), 0.5 μM TGF-b inhibitor A-83--01 (TOCRIS 2939), 0.05 μg/mL EGF (Thermo Fisher PMG8041), 0.1 μg/mL FGF (Peprotech 100--26), 0.01 μM Gastrin I (TOCRIS 3006), 0.1 μg/mL Noggin (Peprotech 250--38), 10.5 μM Rho Kinase Inhibitor Y-27632 (Sigma Y0503), 1.25 mM N-Acetylcysteine (NAC) (Sigma A9165), 10 mM Nicotinamide (Sigma N0636), 1X B-27 supplement (Thermo Fisher 17504), and 1 μg/mL R-spondin. R-spondin was purified from 293 T cells engineered to produce it using a Protein A Antibody Purification Kit (Sigma PURE1A). Organoids were grown in complete media when passaging. For organoid-PSC co-culture experiments, co-cultures were grown in DMEM without pyruvate (Corning 10--017-CV) supplemented with 10% dialyzed FBS and penicillin-streptomycin. Organoids were regularly tested for mycoplasma contamination using the MycoAlert Plus kit (Lonza) or the Mycoprobe Mycoplasma Detection Kit (R and D Systems).

Organoids were digested to single cells by incubating with 2 mg/mL dispase in Advanced DMEM/F12 with penicillin-streptomycin, HEPES, and GlutaMAX at 37°C for 20 min. Organoids were then triturated with a fire-polished glass pipette and enzymatically digested with 1 mL TrypLE Express (Thermo Fisher 12605--010) for 10 min rotating at 37°C, followed by addition of 1 mL of dispase containing media and 10 μL of 10 mg/mL DNAse (Sigma 4527) and digested rotating at 37°C for 20 min or until single cells were visible under a microscope. Cells were counted and plated in GFR matrigel at a concentration of 2000 cells/well.

Proliferation assays {#s4-9}
--------------------

50,000 cells were seeded in six-well plates in 2 mL DMEM with 10%FBS and penicillin-streptomycin. The next day, cells were counted for day 0 and media was changed on remaining cells. 8 mL of media was added and cells were left to proliferate for 3 days. On day 3, cells were trypsinized and counted. Alternatively, proliferation was measured using sulforhodamine B staining as previously described ([@bib88]). Cells were fixed on day 0 and day 3 with 500 µl of 10% trichloroacetic acid (Sigma T9159) in 1 mL media and incubated at 4°C for at least 1 hr. Plates were washed under running water and cells were stained with 1 mL sulforhodamine B (Sigma 230162) and incubated at room temperature for 30 min. Dye was removed and cells were washed three times with 1% acetic acid. Plates were then dried and 1 mL of 10 mM Tris pH 10.5 was added to each well to solubilize the dye. 100 µL of each sample was then transferred to a 96-well plate and absorbance was measured at 510 nm on a microplate reader.

Protein synthesis assays {#s4-10}
------------------------

A fluorescent reporter in which BFP is fused to an unstable *E. coli* dihydrofolate reductase (DHFR) degron domain which is stabilized by trimethoprim ([@bib35]) was used to determine global protein synthesis rate as previously described ([@bib22]). Briefly, PDAC/PSC cell lines and PDAC organoids expressing the reporter were generated by lentiviral transduction and puromycin selection followed by flow cytometry-based sorting for populations that were BFP-positive after TMP addition for 24--48 hr. For each experiment, the reporter protein was stabilized upon addition of 10 uM trimethoprim (TMP) and fluorescence accumulation was measured in cells or organoids by flow cytometry over several time points within 12 hr of TMP addition. Data were normalized to no TMP controls. Puromycin incorporation assays were performed as previously described ([@bib74]). 10 µg/mL puromycin was spiked into the medium of cells grown in 6 cm plates. Plates were kept at 37°C for indicated pulse times (spanning 2.5 to 20 min). As a negative control, 100 µg/mL cycloheximide was added to a plate of cells for 45 min before the addition of puromycin. At the end of the pulse, plates were washed once with ice cold PBS on ice and flash frozen in liquid nitrogen. Cells were harvested from frozen plates by scraping into RIPA buffer containing cOmplete Mini EDTA-free Protease Inhibitor Cocktail (Roche 11836170001) and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche 04906845001) and protein concentration was quantified using the Pierce BCA Protein Assay Kit (Pierce 23225). 2 µL of lysate (approximately 2 µg) was spotted directly onto 0.2 µm nitrocellulose membranes and blotted with primary antibodies against puromycin (Sigma MABE343 1:25,000 dilution) and vinculin (Abcam ab18058, 1:1000 dilution) as a control.

Generation of PC and ME1 knockdown and knockout cells {#s4-11}
-----------------------------------------------------

CRISPRi knockdown cell lines of PC and ME1 were generated by transfecting cells expressing modified dCas9-KRAB fusion protein, as previously described ([@bib39]). The target sequences used for PC sgRNAs were (PC1- GCGGCGGCCACGGCTAGAGG, PC2- GTGGAGGCAGGGGCCGTCAG), the sequence for non-targeting control was GCGACTAGCGCCATGAGCGG, and the target sequence of ME1 sgRNA was GCCGCAGTGGCCTCCCGGGT. After transfection, cells were selected under 5 ug/ml puromycin. Rescue of CRISPRi knockdown cell lines of PC was performed by re-expressing the cDNA of the rescued gene under a CMV promoter using a custom lentiviral construct generated on VectorBuilder and selected in 500 ug/ml blasticidin. CRISPR knockout cell lines for PC and ME1 were generated using the LentiCRISPRv2 system, as previously described ([@bib72]), with guides against the target sequence 5' CGGCATGCGGGTCGTGCATA 3' for PC and 5' GTTTGGCATTCCGGAAGCCA 3' for ME1. After transfection, cells were selected under 5 µg/ml of puromycin, single-cell cloned, and knockout validation performed using western blot. For organoids, the same vector systems and guide sequences were used. Organoids were transfected with concentrated virus by spinfection for 45 min at room temperature. For CRISPR knockout organoids, organoid cultures were selected under 5 µg/ml of puromycin, digested to single cells, and then single organoids were picked, expanded, and validated using western blot.

Double knockout cell lines for PC and ME1 were generated using pUSPmNG (U6 sgRNA PGK with mNeonGreen, [@bib49]) incorporated into cells via electroporation (Amaxa VPI-1005), and selected by FACS using NeonGreen expression. For organoids, double knockout organoids were generated using the LentiCRISPRv2 system and spinfected for 45 min at room temperature. After transfection, cells were selected under 500 ug/ml of blasticidin, digested to single cells, and then single organoids were picked, expanded, and validated using western blot.

Flow cytometry {#s4-12}
--------------

Tumors were dissected, minced, and digested rotating for 30 min at 37°C with 1 mg/mL Collagenase I (Worthington Biochemical LS004194), 3 mg/mL Dispase II (Roche 04942078001), and 0.1 mg/mL DNase I (Sigma D4527) in PBS. Following digestion, cells were incubated with EDTA to 10 mM at room temperature for 5 min. Cells were then filtered through a 70 μm strainer and washed twice with PBS. Single cell suspensions were resuspended in flow cytometry staining buffer (Thermo Fisher 00-4222-57) and first stained with 10 μL of CD16/CD32 monoclonal antibody (Thermo Fisher 14-0161-82) for 15 min to block Fc receptors and then stained using with antibodies to CD45-APC-Cy7 (BD 557659) at 1:100 dilution followed by SYTOX Red Dead Cell Stain (Life Technologies S34859) at 1:1000 dilution to visualize dead cells. All antibodies were incubated for 15--20 min on ice and then washed. Cell sorting was performed with a BD FACS Aria and data was analyzed with FlowJo Software (BD).

Tumor transplantation {#s4-13}
---------------------

100,000 PDAC cells or 100,000 PDAC cells plus 100,000 PSCs in 100 μL PBS were transplanted subcutaneously into the flanks of C57BL/6J mice (000664). Tumors were measured using calipers and volume was calculated using the formula V = (π/6)(L\*W^2^).

For orthotopic transplants, 100,000 PDAC cells in 50 μL PBS were transplanted into the pancreas of C57BL/6J mice (000664) as previously described ([@bib55]).

Immunofluorescence {#s4-14}
------------------

Tumors were fixed in 4% paraformaldehyde (PFA) rotating overnight at 4°C followed by incubation in 30% sucrose in PBS rotating overnight at 4°C. Tumors were then embedded in optimal cutting temperature (OCT) compound and stored at −80°C until sectioning. Sections were stained with antibodies against α-SMA (Sigma F3777, 1:500 dilution), CK19 (Abcam ab133496 1:100), and tdTomato (Rockland 600-401-379, 1:500 dilution) using DAPI as a nuclear stain.

Immunohistochemistry {#s4-15}
--------------------

Sections from formalin fixed paraffin embedded mouse tissue or a human pancreatic cancer tissue microarray (Biomax PA961e) were stained with antibodies against PC (Santa Cruz sc-67021, 1:50 dilution) or ME1 (Proteintech 16619--1-AP, 1:200 dilution). The human pancreatic cancer tissue microarray was scored independently by a pathologist (O.H.Y.), and assigned scores of 0--4 for both staining intensity and percent of cells positive for expression of the indicated protein.

qPCR {#s4-16}
----

RNA was isolated from cells using the RNAqueous-Micro Total RNA Isolation Kit (Life Technologies AM1931) and cDNA was made using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories 1708890). qPCR reactions were performed using SYBR Green Master Mix (Sigma L6544) and primers for pyruvate carboxylase (Forward: 5'- GGG ATG CCC ACC AGT CAC T −3', Reverse: 5'- CAT AGG GCG CAA TCT TTT TGA −3'), malic enzyme 1 (Forward: 5'- TGT GGG AAC AGA AAA TGA GGA GTT −3', Reverse: 5'- TCA TCC AGG AAG GCG TCA TAC T −3'), tdTomato (Forward: 5'- AGC AAG GGC GAG GAG GTC ATC −3' Reverse: 5'- CCT TGG AGC CGT ACA TGA ACT GG −3'), α-sma (Forward: 5'- TCC CTG GAG AAG AGC TAC GAA −3' Reverse: 5'- TAT AGG TGG TTT CGT GGA TGC C −3'), vimentin (Forward: 5'- GTA CCG GAG ACA GGT GCA GT- 3', Reverse: 5'- TTC TCT TCC ATC TCA CGC ATC −3'), Trp53 (Forward: 5'- CTC TCC CCC GCA AAA GAA AAA −3', Reverse: 5'- CGG AAC ATC TCG AAG CGT TTA −3'), CD3ε (Forward: 5'- ATG CGG TGG AAC ACT TTC TGG −3', Reverse: 5'- GCA CGT CAA CTC TAC ACT GGT −3'), F4/80 (Forward: 5'- TGA CTC ACC TTG TGG TCC TAA −3', Reverse: 5'- CTT CCC AGA ATC CAG TCT TTC C −3'), or E-Cadherin (Forward: 5'- GCT CTC ATC ATC GCC ACA G- 3', Reverse: 5'- GAT GGG AGC GTT GTC ATT G- 3') using 18S (Forward: 5'- CGC TTC CTT ACC TGG TTG AT −3', Reverse: GAG CGA CCA AAG GAA CCA TA −3') or 36B4 (Forward: 5'- TCC AGG CTT TGG GCA TCA −3', Reverse: 5'- CTT TAT CAG CTG CAC ATC ACT CAG A −3') as controls. Primer sequences are also included in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Western blot {#s4-17}
------------

Cell lines were washed with ice-cold PBS and scraped into RIPA buffer containing cOmplete Mini EDTA-free Protease Inhibitor Cocktail (Roche 11836170001) and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche 04906845001). Lysates were then rotated at 4°C for 20 min and centrifuged for 5 min at max speed in a tabletop centrifuge at 4°C. Organoids were resuspended in ice-cold PBS containing cOmplete Mini EDTA-free Protease Inhibitor Cocktail and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (PBS-PPI). Organoids were then centrifuged at 3000xg for 3 min at 4°C and washed two times in ice-cold PBS-PPI. Cell pellets were resuspended in TNET buffer (1% Triton X-100, 150 mM NaCl, 5 mM EDTA, and 50 mM Tris ph 7.5) containing cOmplete Mini EDTA-free Protease Inhibitor Cocktail and PhosSTOP Phosphatase Inhibitor Cocktail Tablets, incubated on ice for 10 min, and passed through a 26 gauge needle three times. Lysates were centrifuged for 10 min at max speed in a tabletop centrifuge at 4°C. Protein concentration was quantified using the Pierce BCA Protein Assay Kit (Pierce 23225). Western blots were performed using primary antibodies against PC (Santa Cruz sc-271493, 1:100 dilution), ME1 (Proteintech 16619--1-AP, 1:250 dilution), or β**-**actin (Cell Signaling Technologies 8457, 1:10,000 dilution).

Quantification and statistical analysis {#s4-18}
---------------------------------------

GraphPad Prism software was used for statistical analysis. All statistical information is described in the figure legends.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The manuscript describes a technique that capitalizes on the relatively slow turnover of macromolecules to infer metabolic differences between different cell types within complex tissues, including tumor organoids and intact tumors. The authors use this technique to demonstrate the enhanced use of pyruvate carboxylation in cancer cells relative to fibroblasts, and to show that apparent pyruvate carboxylation uses magic enzyme as well as the more conventional anaplerotic enzyme pyruvate carboxylase.

**Decision letter after peer review:**

Thank you for submitting your article \"Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Ralph DeBerardinis as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard White as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Joshua D Rabinowitz (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

The authors describe an isotope infusion method to infer distinct metabolic activities from distinct cell types within complex organoids and tumors. Because macromolecules like proteins turn over much more slowly than intermediary metabolites, the authors reasoned that proteins would better retain labeling features during ex vivo manipulation to separate different cell types. They find that cancer cells display elevated enrichment of glucose-derived nonessential amino acids in proteins compared to stromal and other non-malignant cells. Labeling in aspartate suggested elevated pyruvate carboxylation in cancer cells, and the authors provide evidence that this carboxylation involves two enzymes: pyruvate carboxylase and malic enzyme-1. Knocking out either enzyme reduced tumor growth. Overall, the paper presents an interesting technique and applies it to advance our understanding of pyruvate carboxylation in pancreatic cancer.

Essential revisions:

1\) Regarding the rationale for assessing label in amino acids for proteins, the authors should place a stronger emphasis on the \"good news\" that TCA labeling patterns are reasonably robust to cell handling. The authors might also make more overt whether or not they tested robustness of these labeling patterns to actual sorting, or just cells sitting in a dish. If they did not test sorting, they might emphasize that, at a minimum, the labeling patterns seem robust enough that the field can be relatively confident of the conclusions of prior work with direct metabolism quenching and TCA metabolite measurement (i.e. the terminal events and delays in quenching in these prior studies are unlikely to have impacted TCA labeling patterns).

2\) Several questions were raised about the relative importance of ME1 and PC for anaplerosis. First, the reader is left with the impression that PC and ME1 are equivalent in their ability to carboxylate pyruvate for anaplerosis/anabolism. But PC is generally considered a unidirectional reaction whereas ME1 is reversible, and the labeling data are certainly consistent with reversibility. The authors should avoid suggesting that malic enzyme has functional redundancy with pyruvate carboxylase until the net direction of ME1 flux is clarified, or if orthogonal evidence is available to support this argument.

3\) Along these lines, the paper does not appear to contain any studies in which ME1 was knocked out but PC left intact. If such data are available (ideally isotope labeling and metabolite levels, but either one would be helpful), this would strengthen the paper. If not, then the authors should be more conservative in their interpretation of ME1\'s role in anaplerosis.

4\) A major long-term question is why pyruvate carboxylase and ME1 are selectively essential in vivo. Why do they become so important when NADPH can also be produced from the oxidative pentose phosphate pathway, and several pathways are available for anaplerosis? This issue deserves more attention in the Discussion.

5\) In Figure 1, the authors show labeling of glucose in the plasma, and comment that products of glycolysis (pyruvate, lactate, alanine) are labeled in the tumor. Because these metabolites can be readily taken up by some tissues, their labeling in the blood should also be reported. Labeling in circulating aspartate should also be reported.

6\) If available already from some of the MS analyses conducted for labeling, it would be helpful to see more data on metabolite concentrations (relative concentrations would be sufficient), especially for key players such as malate, aspartate, pyruvate and, if appropriate methods were used to acquire the data, NADPH, NADP, NADH and NAD.

7\) Glucose enrichment in plasma is provided, but not glucose enrichment in the tumors. If these values differ among the tumor models (WT, KP-/-C, KPC), this might explain some differences in labeling of downstream, metabolites. If these measurements are available, they should be included. Plasma insulin levels in the different models should also be provided if available.
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Author response

> Essential revisions:
>
> 1\) Regarding the rationale for assessing label in amino acids for proteins, the authors should place a stronger emphasis on the \"good news\" that TCA labeling patterns are reasonably robust to cell handling. The authors might also make more overt whether or not they tested robustness of these labeling patterns to actual sorting, or just cells sitting in a dish. If they did not test sorting, they might emphasize that, at a minimum, the labeling patterns seem robust enough that the field can be relatively confident of the conclusions of prior work with direct metabolism quenching and TCA metabolite measurement (i.e. the terminal events and delays in quenching in these prior studies are unlikely to have impacted TCA labeling patterns).

This is a reasonable point, and our intention was neither to question prior work examining TCA cycle labeling in sorted cells nor to imply that approach does not generate interesting data. We have modified our Discussion to make this more clear. Nevertheless, we are hesitant to overemphasize that TCA cycle labeling is robust with respect to sorting in all cases. While we agree that in the cells and conditions we tested, some metabolite labeling patterns and levels were robust to cell handling, this was not the case for all TCA metabolites. As reviewed in Buescher et al., 2015, interpretation of isotope labeling often assumes both isotopic and metabolic steady-state where neither levels nor labeling patterns are changing. We are the first to admit that from a practical standpoint, one can still derive interesting information from labeling studies even in conditions where isotopic and metabolic steady-state are not achieved (including in this study where we do not reach steady-state labeling of amino acids in protein). We discuss these points in the revised manuscript and stress that we are not calling into question the conclusions of prior work.

Regarding the question about whether our control experiments considered actual cell sorting or cells siting in a dish, we did not explicitly test how sorting cells affects metabolite labeling or levels. Rather, we focused our control experiments on the effects of processing time as this was most relevant to the data we included in the study. We thank the reviewers for asking us to clarify this important point. In the revised manuscript we discuss that we did not directly test the effect of sorting, but rather the effect of time before cell metabolites are extracted and that any further effects of sorting on free metabolites was not addressed by our analysis.

> 2\) Several questions were raised about the relative importance of ME1 and PC for anaplerosis. First, the reader is left with the impression that PC and ME1 are equivalent in their ability to carboxylate pyruvate for anaplerosis/anabolism. But PC is generally considered a unidirectional reaction whereas ME1 is reversible, and the labeling data are certainly consistent with reversibility. The authors should avoid suggesting that malic enzyme has functional redundancy with pyruvate carboxylase until the net direction of ME1 flux is clarified, or if orthogonal evidence is available to support this argument.

We thank the reviewers for pointing this out, as we did not intend to suggest ME1 and PC are functionally redundant. Please see our response to related point 3 below for a discussion of further data and how we modified the text to correct this issue.

> 3\) Along these lines, the paper does not appear to contain any studies in which ME1 was knocked out but PC left intact. If such data are available (ideally isotope labeling and metabolite levels, but either one would be helpful), this would strengthen the paper. If not, then the authors should be more conservative in their interpretation of ME1\'s role in anaplerosis.

Again this is an important point and we agree fully with the reviewers' comments. As the reviewers appreciate, it is difficult to quantitatively determine the flux in cells where both PC and ME1 can contribute to anaplerosis, and agree that these activities are unlikely to be equivalent. Indeed we did perform experiments where ME1 was knocked out and PC left intact. The isotope labeling data from those ME1 null cells unexpectedly showed a larger decrease in labeling consistent with pyruvate carboxylation than was observed in PC null cells (with ME1 left intact). We originally opted not to include these data in the manuscript so as not to mislead readers who might conclude ME1 is more important for anaplerosis than PC. This implication would be quite controversial, and in our view is not a conclusion that should be drawn based only on these data. Furthermore, as discussed in the manuscript, carbon cycling involving both enzymes is likely when both enzymes are present, and dissecting pyruvate cycling is a formidable challenge. This led us to conclude that both PC and ME1 can contribute to anaplerotic TCA flux, but this study cannot distinguish between the relative activities of the two enzymes.

Nevertheless, the point raised by the reviewers is appreciated as we agree this is an obvious experiment some readers might expect, and despite our reservations about interpretation, we concur that isotope-labeling data from ME1 single knockout cells does strengthen the conclusion that ME1 can contribute to TCA cycle anaplerosis in pancreatic cancer. Thus, we have included the isotope-labeling experiments where ME1 was knocked down or knocked out and PC was left intact in Figure 7---figure supplement 1 of the revised manuscript. This includes data showing cells with reduced or absent levels of ME1 have reduced M+1 aspartate labeling from 1-^13^C-pyruvate. We also include a discussion that these data should not necessarily be used to conclude that flux through ME1 is higher than PC, particularly in cells where both enzymes are expressed.

Functional experiments in which ME1 was knocked out with PC left intact remain in Figure 7 of the manuscript. The effects of ME1 knockout show a similar effect to PC knockout, with minimal effects on cell proliferation in culture (Figure 7F), but a reduction in organoid growth (Figure 7G-H) and tumor formation (Figure 7I).

> 4\) A major long-term question is why pyruvate carboxylase and ME1 are selectively essential in vivo. Why do they become so important when NADPH can also be produced from the oxidative pentose phosphate pathway, and several pathways are available for anaplerosis? This issue deserves more attention in the Discussion.

We agree that this is an interesting topic and will be an important question for future research. We now include additional discussion of the selective in vivo essentiality of PC and ME1 in the Discussion section of the revised manuscript.

> 5\) In Figure 1, the authors show labeling of glucose in the plasma, and comment that products of glycolysis (pyruvate, lactate, alanine) are labeled in the tumor. Because these metabolites can be readily taken up by some tissues, their labeling in the blood should also be reported. Labeling in circulating aspartate should also be reported.

We agree that labeling of plasma metabolites other than glucose is informative and should be reported. We apologize for this oversight in the original manuscript and now include these data in Figure 1---figure supplements 1-3 of the revised manuscript and in the source data files. Regarding the labeling of circulating aspartate, we point out that prior work using this model has shown that aspartate is not accessible to these cancer cells (Sullivan et al., 2018) and so plasma labeling from this metabolite will minimally contribute to labeling in PDAC tumors.

> 6\) If available already from some of the MS analyses conducted for labeling, it would be helpful to see more data on metabolite concentrations (relative concentrations would be sufficient), especially for key players such as malate, aspartate, pyruvate and, if appropriate methods were used to acquire the data, NADPH, NADP, NADH and NAD.

All mass spectrometry data were collected using GC-MS and therefore unfortunately NADPH, NADP, NADH, and NAD were not measured in this study. We also agree that relative concentrations of metabolites are important to include and we apologize for omitting these data from the original manuscript. Relative levels of metabolites measured from the infusion experiments are now included in Figure 1---figure supplements 1-2 and in the source data files for the revised manuscript.

> 7\) Glucose enrichment in plasma is provided, but not glucose enrichment in the tumors. If these values differ among the tumor models (WT, KP-/-C, KPC), this might explain some differences in labeling of downstream, metabolites. If these measurements are available, they should be included. Plasma insulin levels in the different models should also be provided if available.

Unfortunately we did not measure glucose enrichment in tumors for these infusion experiments. Since glucose is thought to be rapidly metabolized after entry into tumor cells, we expect that any measurements of labeled glucose from tumor tissue to reflect labeling of glucose in plasma as has been observed in other contexts, but point out in the revised manuscript that this was not explicitly confirmed in this study.

We also did not measure plasma insulin as part of these experiments; however, in our previous work plasma insulin levels were measured in PDAC tumor bearing mice from the same KP^-/-^C mouse model and compared to levels in wild-type mice. In those studies, no significant differences in plasma insulin levels were observed in either the fed or fasted states, or after a glucose injection which substantially raises glucose levels, between the control and tumor bearing animals (Danai et al., 2018).
